

# Efficacy and Safety of Curcumin and *Curcuma longa* Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial

## OPEN ACCESS

#### Edited by:

Markus H. Hoffmann, University of Lübeck, Germany

### Reviewed by:

Sadiq Umar, University of Illinois at Chicago, United States Zhengping Huang, Guangdong Second Provincial General Hospital, China

#### \*Correspondence:

Hua Chen chhuaa332211@163.com Liuting Zeng zttab2016@hotmail.com Tiejun Yang yangtiejun321@outlook.com Kailin Yang yklab2014@hotmail.com

### Specialty section:

This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology

> Received: 08 March 2022 Accepted: 22 April 2022 Published: 22 July 2022

#### Citation:

Zeng L, Yang T, Yang K, Yu G, Li J, Xiang W and Chen H (2022) Efficacy and Safety of Curcumin and Curcuma longa Extract in the Treatment of Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. Front. Immunol. 13:891822. doi: 10.3389/fimmu.2022.891822 Liuting Zeng<sup>1\*†</sup>, Tiejun Yang<sup>2\*†</sup>, Kailin Yang<sup>3\*</sup>, Ganpeng Yu<sup>2</sup>, Jun Li<sup>2</sup>, Wang Xiang<sup>4</sup> and Hua Chen<sup>1\*</sup>

<sup>1</sup> Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China, <sup>2</sup> Department of Orthopedics, People's Hospital of Ningxiang City, Ningxiang City, China, <sup>3</sup> Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, Hunan University of Chinese Medicine, Changsha City, China, <sup>4</sup> Department of Rheumatology, The First People's Hospital Changde City, Changde City, China

**Background:** Modern pharmacological research found that the chemical components of *Curcuma longa L.* are mainly curcumin and turmeric volatile oil. Several recent randomized controlled trials (RCT) have shown that curcumin improves symptoms and inflammation in patients with arthritis.

**Methods:** Pubmed, Cochran Library, CNKI, and other databases were searched to collect the randomized controlled trials (RCTs). Then, the risk of bias of RCTs were assessed and data of RCTs were extracted. Finally, RevMan 5.3 was utilized for meta-analysis.

**Results:** Twenty-nine (29) RCTs involving 2396 participants and 5 types of arthritis were included. The arthritis included Ankylosing Spondylitis (AS), Rheumatoid Arthritis (RA), Osteoarthritis (OA), Juvenile idiopathic arthritis (JIA) and gout/hyperuricemia. Curcumin and Curcuma longa Extract were administered in doses ranging from 120 mg to 1500 mg for a duration of 4-36 weeks. In general, Curcumin and Curcuma longa Extract showed safety in all studies and improved the severity of inflammation and pain levels in these arthritis patients. However, more RCTs are needed in the future to elucidate the effect of Curcumin and Curcuma longa Extract supplementation in patients with arthritis, including RA, OA, AS and JIA.

**Conclusion:** Curcumin and Curcuma longa Extract may improve symptoms and inflammation levels in people with arthritis. However, due to the low quality and small quantity of RCTs, the conclusions need to be interpreted carefully.

Keywords: curcumin, *Curcuma longa* extract, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, juvenile idiopathic arthritis, systematic review, meta-analysis

# **1 INTRODUCTION**

Arthritis is a general term for various types of arthritic diseases, which are related to various factors such as degenerative diseases and autoimmunity. It is characterized by chronic inflammation of one or more joints, which usually causes pain and is often disabling. The main clinical symptoms are joint pain, swelling, stiffness, and limited mobility (1, 2). Epidemiology shows that arthritis is the most common in women, and the incidence of arthritis increases with age. Meanwhile, the prevalence of arthritis of different etiologies varies in the population (3, 4). Current research shows that there are more than 100 different forms of arthritis, with osteoarthritis (OA) and rheumatoid arthritis (RA) being the most common; other types mainly include arthritis associated with autoimmune diseases (5-7). Although these disorders have different etiologies, all of them are characterized by pain and limited mobility due to joint inflammation (7). At present, the drugs and non-drug methods for the treatment of arthritis are mainly related to the progression of joint pain and tissue joint inflammation, especially in the treatment of pain, the drugs are basically the same (8, 9). Among them, OA is a degenerative joint disease, the number of which is increasing with the aging of the population (10). According to the World Health Organization (WHO) survey, there are currently more than 400 million patients with osteoarthritis worldwide. In Asia, 1 in 6 people will develop OA at some point in their life. OA is more common in middle-aged and elderly people, and more women than men (11). Market research reports show that the OA therapeutics market was estimated at USD 6.8 billion in 2019 and is expected to reach USD 10.1 billion by 2024, growing at a CAGR of 8.1% from 2019 to 2024. The report shows that this increase is partly due to the rapid increase in the elderly and obese population and the consequent increase in the prevalence of OA (12-14). Rheumatoid arthritis (RA) is an autoimmune disease with erosive arthritis as the main symptom. The main symptoms are joint morning pain, swelling, pain and dysfunction. As a systemic inflammatory and destructive joint disease, the prevalence in the adult population worldwide is approximately 1-2% (15, 16). At present, RA is still difficult to cure, but standard diagnosis and treatment can achieve standard treatment. However, without regular treatment, it can lead to joint deformity and loss of function (17). Other types of arthritis are also associated with inflammation and pain, causing a huge burden on patients, but there is still no treatment for the underlying cause.

The main goal of current arthritis treatment is to reduce joint pain caused by joint inflammation, daily wear and tear of the joint, and muscle strain (18). Existing drugs for the treatment of arthritis are analgesics, steroids and non-steroidal antiinflammatory drugs (NSAIDs), as well as biologically targeted drugs, which reduce symptoms such as severe pain and inflammation (19, 20). However, these drugs have a large number of side effects, which prevent them from providing sustained relief of disease symptoms and progression after long-term use. For example, the side effects of NSAIDs are severe gastrointestinal tract and insufficient pain relief after drug treatment, and biologically targeted drugs have immune disorders and adverse cardiovascular events (21–23). Therefore, the current treatment of arthritis has entered the stage of comprehensive management and treatment, and replacement therapy has gradually become an important part of the comprehensive management and treatment model (24, 25).

Curcuma longa L. is a potential alternative medicine for the treatment of arthritis, and they have been used as many ethnic medicines and gourmet condiments in several countries including China, Bangladesh, India and Pakistan (26). They have long been used as anti-inflammatory treatments in traditional Chinese medicine (TCM) and Ayurvedic medicines (27). The main components of turmeric are curcumin and demethoxycurcumin, bisdemethoxycurcumin and turmeric essential oil. Among them, curcumin is a natural compound, and current studies have shown that curcumin has good anti-inflammatory, immunosuppressive and anticancer properties (28-30). Evidence from multiple clinical trial studies suggests that curcumin can reduce the subjective experience of pain in patients with system-related disorders of muscle disease. Therefore, it is very important to systematically review the effects of Curcuma longa L. and curcumin in patients with arthritis.

# **2 MATERIALS AND METHODS**

## 2.1 Protocol

This systematic review and meta-analysis were conducted strictly in accordance with the protocol (CRD42022286421) and PRISMA-guidelines (see **Supplementary Materials**).

# 2.2 Literature Search Strategy

Web of Science, Cochrane Library, PubMed, The ClinicalTrials.gov, China Biology Medicine (CBM), VIP Database, China National Knowledge Infrastructure (CNKI), MEDLINE Complete, Wanfang Database, Embase were searched for RCTs related to Curcumin and Curcuma longa Extract in the treatment of arthritis. The search period is from the establishment of the database to Fib. 2022. The search strategy of Pubmed and Embase is shown in **Table S1** as an example.

## 2.3 Selection Criteria

(1) Participants: Patients diagnosed with any type of arthritis by recognized standards. (2) Intervention: the intervention of experimental group is curcumin, with no restrictions on dosage, dosage form, and usage; the intervention of control group can be non-curcumin interventions such as placebo and conventional therapy. (3) Outcomes: Efficacy indicators, inflammatory indicators, adverse events. (4) Study design: RCTs

# 2.4 Literature Screening, Data Extraction and Quality Assessment

Two researchers independently reviewed the literature according to Selection criteria, and conducted literature screening and data extraction. If there are differences, they should be resolved through consultation and discussion. The literature quality evaluation uses the risk bias assessment tool of the systematic reviewer manual recommended by the Cochrane Collaboration to evaluate the methodological quality of the included studies (31). The content of the assessment includes random allocation method, allocation concealment, whether blind method is used for participants, the completeness of the result data, whether there is selective reporting, and other biases.

## 2.5 Statistical Analysis

The RevMan 5.3 software recommended by the Cochrane Collaboration was used for meta-analysis. The risk ratio (RR) or mean difference (MD) and its 95% confidence interval (CI) are used as the efficacy and safety statistics. The  $\chi 2$  test is used to evaluate the heterogeneity of the literature. P  $\geq$  0.1 or I 2  $\leq$  50% means that the studies are homogeneous. The studies can be combined and analyzed using a fixed-effects model; otherwise, a random-effects model is used for analysis.

# **3 RESULTS**

## 3.1 Results of the Search

According to the search strategy, 1981 related papers were initially retrieved. After deduplication, reading the title and abstract, and the full text, 30 RCTs were finally included, while 7 records were excluded (32–38) (**Figure 1**).


## **3.2 Description of Included Trials**

The included RCTs involved 5 types of arthritis: RA, AS, OA, Juvenile idiopathic arthritis (JIA) and gout/hyperuricemia; they

also involved 11 countries: Iran, India, China, Australia, Belgium, Armenia, Indonesia, Thailand, Japan, Italy, Romania. The study size is between 20-200 participants. The drugs in the experimental group involved curcumin, curcuminoids and Curcuma longa Extract, and their types of preparation were different. 39, 40 and 41 used two different doses of curcumin intervention (highdose group and low-dose group), so they are divided into 39 a (low-dose group), 39 b (high-dose group), 40 (low-dose group), 40 (high-dose group), 41 (low-dose group) and 41 (high-dose group). The interventions of Chandran et al. (42) were divided into Curcumin 500 mg and Curcumin 500 mg+diclofenac sodium 50 mg, so they were also divided into Chandran et al. (42) (Curcumin only) and Chandran et al. (42) (Curcumin +Diclofenac sodium). At the same time, their control group was divided into two groups, matching the two experimental groups. 43 include 2 experimental groups and 2 control groups; it was divided into 43 (Curcuma longa Extract v.s. placebo) and 43 (Curcuma longa Extract+Glucosamine v.s. Glucosamine). The details of study characteristics are presented in Table 1.

# **3.3 Risk of Bias Assessments** 3.3.1 Selection Bias

Nine RCTs did not described the random sequence generation methods and were rated as unclear risk of bias (39, 40, 44, 49, 51, 54, 60, 63–65). Other studies have explained the method of generating random sequences, so they are assessed as low risk of bias.



Disease	RCTs	Country	Parti	nber of cipants ale/male)	Intervention		Outcomes	Age (ye	ears)		rse of e (years)	Duration
			Trial	Control	Trial	Control		Trial	Control	Trial	Control	
RA	Javadi et al. (44)	Iran	21/3	23/2	Curcumin nanomicelles 40mg Tid	wheat flour (placebo) 500mg Tid	DAS28, Tender joint count, Swollen joint count, ESR, adverse events	53.71 ± 2.75	56.28 ± 2.5	8.5 ± 9.08	7.36 ± 5.29	12 weeks
	Amalraj et al. (39)	India	8/16	7/5	Curcumin 250mg or 500mg	placebo	DAS28, ESR, CRP, Tender joint count, Swollen joint count, RF, adverse events	36.7 ± 10.7 (250mg); 38.3 ± 5.8 (500mg)	39.6 ± 8.8	-	-	12 weeks
	Jacob et al. (40)	India	7/9	5/3	Curcumin 250mg or 500mg	placebo	DAS28, ESR, CRP, RF	18-65	18-65	-	-	12 weeks
	Chandran et al. (42)	India	24/6	14/1	Curcumin 500 mg or Curcumin 500 mg+diclofenac sodium 50 mg	Diclofenac sodium 50 mg	DAS28, ESR, CRP, adverse events	$47.8 \pm 8.60$ (Curcumin only); $47 \pm 16.22$ (combination)	48.87 ± 10.78	-	_	8 weeks
	Lin et al. (45)	China	32/32	33/31	Curcumin 100 mg Tid +Methotrexate 12.5mg once a week	Methotrexate 12.5mg once a week	DAS28, adverse events	48.39 ± 9.70	45 ± 10.31	9.43 ± 7.93	11.94 ± 8.02	12 weeks
	Pourhabibi- Zarandi et al. (46)	Iran	22/0	22/0	Curcumin 500 mg	placebo	ESR, CRP	50.68 ± 9.93	50.36 ± 9.70	9.77 ± 3.49	8.09 ± 3.13	8 weeks
OA	Hashemzadeh et al. 2007 (47)	Iran	29/7	31/4	Curcuminoids (SinaCurcumin <sup>™</sup> ) 40mg	Placebo	WOMAC score, adverse events	54.11 ± 5.80	56.54 ± 5.77	4.51 ± 0.48	4.71 ± 0.48	6 weeks
		Italy	14/9	19/8	CartiJoint Forte (containing glucosamine hydrochloride (GH), chondroitin sulfate (CS) and Bio- Curcumin) + physical therapy	Placebo + physical therapy	VAS, WOMAC score, adverse events	71.3 ± 8.8	71.0 ± 8.0	6.8 ± 7.6	7.2 ± 6.0	8 weeks
	Haroyan et al. (48)	Armenia	62/5	65/3	Curcuminoids 999mg (CuraMed <sup>®</sup> 1500mg)	Placebo	WOMAC score, ESR, CRP, adverse events	54.65 ± 8.84	$56.04 \pm 8.55$	-	-	12 weeks
	Nakagawa et al. (49)	Japan	14/4	18/5	Curcumin 180 mg	Placebo	VAS, adverse events	71.9 ± 5.3	66.1 ± 7.2	-	-	8 weeks
	Madhu et al. (43)	India	41/19	42/18	Curcuma longa Extract 1000 mg or Curcuma longa Extract 1000 mg+ Glucosamine 1500 mg	Glucosamine 1500 mg or Placebo (Microcrystalline cellulose) 800mg	VAS, adverse events	56.63 ± 10.58; 58.17 ± 9.30	56.80 ± 7.99; 56.77 ± 9.98	_	_	6 weeks
	Srivastava et al. (50)	India	53/25	50/32	Curcuma longa Extract 500 mg +Diclofenac 50 mg	Placebo 500mg +Diclofenac 50 mg	VAS, WOMAC score, adverse events	50.23 ± 8.08	50.27 ± 8.63	-	-	16 weeks
	Khanna et al. (51)	India	42/38		Curcumagalactomannosides 400mg + glucosamine hydrochloride 500mg	Chondroitin sulphate 415 mg+ glucosamine hydrochloride 500 mg	VAS, WOMAC score	53.4 ± 6.64	51.5 ± 5.95	-	-	12 weeks
	Shep et al. (52)	India	48/21	45/25	Curcumin (BCM-95 <sup>®</sup> ) 1500 mg	Diclofenac sodium	VAS, KOOS, adverse events	53.09 ± 4.17	52.14 ± 3.76	0.62 ± 0.29	0.62 ± 0.26	4 weeks
	Thomas et al. (53)	India	16/19	21/16	Curcuminoids 500mg	Chondroitin sulphate 830 mg+	VAS, WOMAC score, adverse events	51.7 ± 5.52	52.3 ± 4.59			6 weeks

(Continued)

TABLE 1	Continued
---------	-----------

Disease	RCTs	Country	Partic	ber of cipants le/male)	Intervention		Outcomes	Age (y	ears)		rse of e (years)	Duratio
			Trial	Control	Trial	Control		Trial	Control	Trial	Control	
						glucosamine hydrochloride 1000 mg						
	Wang et al. (24)	Australia	18/18	21/13	Curcuma longa Extract 1000 mg	Placebo	VAS, WOMAC score, adverse events	61.3 ± 8.5	62.4 ± 8.8	-	-	12 weeks
	Pinsornsak et al. (54)	Thailand	62/13		Curcumin 1000 mg+diclofenac 75 mg	Diclofenac 75 mg	VAS	-	-	-	-	12 weeks
	Jamali et al. (55)	Iran	22/14	23/13	Curcumin ointment	Placebo (Vaseline ointment)	VAS, adverse events	68.86±6.27	$67.94 \pm 6.72$	7.22 ± 4.46	6.91 ± 4.68	6 weeks
	Kuptniratsaikul et al. (56)	Thailand	41/11	45/10	Curcuma longa Extract 2000 mg	lbuprofen 800 mg	VAS, adverse events	61.4 ± 8.7	60.0 ± 8.4	1.59 ± 1.63	1.86 ± 2.2	6 weeks
	Kuptniratsaikul et al. (57)	Thailand	157/14	139/21	Curcuma longa Extract 1500 mg	lbuprofen 1200 mg	WOMAC score, adverse events	$60.3 \pm 6.8$	$60.9 \pm 6.9$	4.28 ± 4.45	4.33 ± 4.31	4 weeks
	Panahi et al. (58)	Iran	14/5	17/4	Curcuminoid 1500mg	Placebo (inert starch)	VAS, WOMAC score, adverse events	57.32 ± 8.78	57.57 ± 9.05	-	-	6 weeks
	Lopresti et al. (59)	Australia	24/27	26/24	Curcuma longa Extract (Curcugen) 1000mg	Placebo	KOOS, adverse events	59.59 ± 6.57	57.92 ± 6.22	-	-	8 weeks
	Henrotin et al. (41)	Belgium	79/17	34/11	Curcuma longa Extract 280mg or 197mg	Placebo	VAS, KOOS, adverse events	60.9 ± 9.78; 61.4 ± 7.49	63.3 ± 7.69	7.41 ± 7.29; 6.6 ± 4.67	7.6 ± 9.3	12 weeks
	Kertia et al. (60)	Indonesia	24/15	29/12	Curcuminoid 90mg	Diclofenac sodium 90mg	COX-2	64.05 ± 8.83	64.56 ± 8.86	3.44 ± 2.72	3.36 ± 2.57	4 weeks
	Panahi et al. (66)	Iran	14/5	17/4	Curcuminoids (C3 complex <sup>®</sup> ) 1500 mg	Placebo (inert starch)	SOD, GSH, MDA	57.32 ± 8.78	57.57 ± 9.05	-	-	6 weeks
	Gupte et al. (61)	India	11/6	23/2	Curcuma longa Extract 800mg	lbuprofen + placebo	VAS, WOMAC score, adverse events	57 ± 7.5	54 ± 8	almo	st 1-11	6 weeks
AS	Ahmadi et al. (Ahmadi et al., 2020 (62)	Iran	12/0	12/0	Nanocurcumin	Placebo	Inflammatory factor	23-32	27-46	3-22	6-17	16 weeks
Juvenile oligoarthritis	Ailioaie and Ailioaie (63)	Romania	`	16 (not known)	Protein Curcumin Complex 1800mg	Placebo	VAS, ACR Pedi30, ACR Pedi50, ACR Pedi70, ACR Pedi90, adverse events	8-1	6	-	-	36 weeks
	Ailioaie and Ailioaie (64)	Romania		20 (not known)	Ultra Bioavailable Curcumin 1200mg	Placebo	JADAS-71	Mean:	13.8	-	-	24 weeks
Gout/ hyperuricemia	Bupparenoo	Thailand	20 (8/ 12)	19 (7/ 12)	Curcumin 1000mg	Placebo	Serum uric acid, urine uric acid clearance, fasting plasma glucose, blood lipids, adverse events	55.5 ± 8.7	55.2 ± 13.0	-	_	8 weeks

63 and 39, 40, 45, 51, 60, 64, 66 did not specify whether to perform allocation concealment and were therefore assessed as unclear risk of bias. Other studies have described the method of allocation concealment, so they are assessed as low risk of bias.

### 3.3.2 Performance Bias and Detection Bias

39, 40, 42, 49–51, 63 and 54, 58, 64, 65 stated that they used blinding, but did not describe how the blinding was performed, and was rated as unclear risk of bias. 45, 52, 53, 61 did not describe whether blinding was used, and its primary outcome is subjective evaluation index, which is easily affected by nonblinding, so it is assessed as a high risk of bias. 56 described only the blinding for outcome assessment and not the blinding of patients, it was rated as low risk for blinding of outcome assessment and high risk for bling of participants and personnel. 43 used blinding only on the participants, not the measurers, and thus it was rated as having low risk of bias in performance bias and having high risk of bias in detection bias. The other RCTs described the method blind implementation to patients and researchers or their outcomes are objective indicators, and are therefore considered to be a low risk of bias.

### 3.3.3 Attrition Bias and Reporting Bias

The remaining RCTs did not have incomplete outcomes or the reasons for the missing and the number are balanced, hence they are therefore assessed as low risk of bias. Allioaie and Ailioaie 63 and Allioaie and Ailioaie 64 only have abstracts and no proposals for outcomes, so we do not have enough information to rate whether there is selective reporting, so it is assessed as unclear

risk of bias. The other RCTs do not have selective reporting and are therefore considered to be a low risk of bias.

### 3.3.4 Other Potential Bias


Ailioaie and Ailioaie 2018 only have abstracts, so we do not have enough information to rate whether there is selective reporting, so it is assessed as unclear risk of bias. 39–41, 49, 51, 53, 54, 59, 67, 68 claimed that authors have received funding from company that produces curcumin or Curcuma longa Extract; or that claimed that authors are the employees of company that produces curcumin or Curcuma longa Extract, hence they were rated as high risk of bias. Other sources of bias were not observed in 5 RCTs; therefore, the risks of other bias of the RCTs were low. (**Figure 2**)


# 3.4 The Outcomes for RA

### 3.4.1 Efficacy Indicators

(1) DAS28: Five (5) RCTs reported the DAS28. The result of heterogeneity analysis was I2 = 85% and P<0.00001, which showed that there was statistical heterogeneity among the 5 studies, so the random effects model was used. The results of Meta analysis showed that there was a statistical difference between the experimental group and the control group (P<0.0001), which indicates that curcumin may decrease DAS28 [WMD -1.06 (-1.53, -0.59)] (Figure 3).

(2) tender joint count: Two (2) RCTs reported the tender joint count. The result of heterogeneity analysis was I2 = 95% and P<0.00001, which showed that there was statistical heterogeneity among the 2 studies, so the random effects model was used. The results of Meta analysis showed that the difference between the experimental group and control group is of no statistical significance [SMD -3.91 (-8.60, 0.78), P=0.10] (**Figure 4A**).





(3) swollen joint count: Two (2) RCTs reported the swollen joint count. The result of heterogeneity analysis was I2 = 95% and P<0.00001, which showed that there was statistical heterogeneity among the 2 studies, so the random effects model was used. The results of Meta analysis showed that the difference between the experimental group and control group is of no statistical significance [SMD -3.75 (-8.32, 0.81), P=0.11] (Figure 4B).

#### 3.4.2 Inflammatory Indicator

(1) ESR: Five (5) RCTs reported the ESR. The result of heterogeneity analysis was I2 = 91% and P<0.00001, which showed that there was statistical heterogeneity among the 5 studies, so the random effects model was used. The results of Meta analysis showed that there was a statistical difference between the experimental group and the control group

(P<0.0001), which indicates that curcumin may decrease ESR [SMD -3.09 (-4.60, -1.58)] (**Figure 5A**).

(2) CRP: Four (4) RCTs reported the CRP. Since Chandran and Goel (42) differed in baseline CRP, the endpoint results were not comparable and the data were excluded. The result of heterogeneity analysis was I2 = 93% and P<0.00001, which showed that there was statistical heterogeneity among the 4 studies, so the random effects model was used. The results of Meta analysis showed that there was a statistical difference between the experimental group and the control group (P=0.0005), which indicates that curcumin may decrease CRP [WMD -0.35 (-0.55, -0.15)] (Figure 5B).

(3) RF: Two (2) RCTs reported RF. The result of heterogeneity analysis was I2 = 0% and P=0.97, which showed that there was no statistical heterogeneity among the 2 studies, so the fixed effects model was used. The results of Meta analysis

$B_{Avadi et al. 2019} \underbrace{2 43 \ 2 01 \ 2 4 \ 2 2 \ 2 \ 2 \ 2 \ 3 5 \ 3 \%}_{Avadi et al. 2017} \underbrace{- 0.06 \ [-0.64, 0.44]_{-0.67, 0.44}_{-0.65, 0.6, 3.41}_{-0.65, 0.6, 3.41}_{-0.65, 0.6, 3.41}_{-0.65, 0.6, 3.41}_{-0.65, 0.6, 3.41}_{-0.65, 0.6, 3.41}_{-0.65, 0.6, 3.41}_{-0.65, 0.6, 3.41}_{-0.65, 0.6, 3.41}_{-0.65, 0.6, 0.6, 0.6, 0.6, 0.6, 0.6, 0.6, 0.6$			Experiment		ontrol		Std. Mean Difference	Std. Mean Difference	Risk of Bias
Analraj et al. 2017b 2. 58 0.67 12 10.67 1.97 6 32.2% $-5.75 [\pm 0.05, 3.41]$ Amalraj et al. 2017b 2.58 0.67 12 10.67 1.97 6 32.2% $-5.25 [\pm 8.75, 3.74]$ Total (95% C) 48 37 100.0%; Test for overall effect: $Z = 1.63 (P = 0.10)$ Binding of auticome data (attrition bias) (B) Allocation conceasiment (selection bias) (B) Binding of outcome data (attrition bias) (B) Selective reporting (reporting bias) (B) Control Selection Dias) (B) Selective reporting (reporting bias) (C) Other biases		Study or Subgroup					IV. Random, 95% CI	IV. Random, 95% Cl	A B C D E F G
Amalraj et al. 2017b 2.58 0.67 12 10.67 1.97 6 32.2% -6.25 ( $\frac{1}{8}$ .75, -3.74 Total (9%, C) 48 37 100.0% Heterogeneity: Tau <sup>2</sup> = 16 18; Ch <sup>2</sup> = 4.136, df = 2 (P < 0.00001); P = 95% Test for verail effect: Z = 1.63 (P = 0.10) Risk of bias legend. (A) Random sequence generation (selection bias) (C) Blinding of participants and personnel (performance bias) (B) Blinding of participants and personnel (performance bias) (G) Other biases B S S S S S S S S S S S S S								-	77744
Total (95% CI) 48 37 100.0% Heterogeneity: Tau <sup>2</sup> = 16.18: Ch <sup>2</sup> = 41.36, df = 2 (P < 0.00001); P = 95% Test for overall effect: Z = 1.63 (P = 0.10) Risk of bias legend. (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (B) Allocation concealment (selection bias) (B) Allocation concealment (selection bias) (B) Binding of autome assessment (detection bias) (B) Binding of autome data (attrition bias) (B) Selective reporting (reporting bias) (B) Control Stat. Mean Difference Mean SD Total Mean SD Total Weight V. Random. 95% CI Availed is 1.2019 12.1 1.53 24 1.24 1.66 25 35.2% - 0.02 (D.58, 0.54) Availed is 1.2017 2.92 0.67 12.9 9.92 1.93 6 32.0% - 5.48 (P.75, 5.3.24) Availe is 1.2017 2.92 0.74 12 9.92 1.93 6 32.1% - 6.08 [-6.53, -3.63] Total (95% CI) 48 37 100.0% Heterogeneity: Tau <sup>2</sup> = 15.30; Ch <sup>2</sup> = 4.14.3, df = 2 (P < 0.00001); P = 95% Test for overall effect: Z = 1.61 (P = 0.11) Risk of Bias Risk of Bias Risk of Bias Risk of Bias Risk of Bias Risk of Bias Total (95% CI) 48 37 100.0% Heterogeneity: Tau <sup>2</sup> = 15.30; Ch <sup>2</sup> = 4.14.3, df = 2 (P < 0.00001); P = 95% Test for overall effect: Z = 1.61 (P = 0.11) Risk of Bias Risk of Bias								-	
Heterogenetic: Tau <sup>2</sup> = 16.18: Ch <sup>2</sup> = 41.38, df = 2 (P < 0.00001); P = 95% Test for overall effect: Z = 1.63 (P = 0.10) Risk of bias legend. (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome data (attrition bias) (C) Blinding of outcome data (attrition bias) (C) Cher biases B Total (95% C) Total (95% C) Total (95% C) Risk of bias legend. (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome data (attrition bias) (C) Cher biases B Total (95% C) Total (95% C) Risk of bias legend. (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Cher biases B Total (95% C) Risk of bias legend. (A) Random sequence generation (selection bias) (B) Blinding of outcome assessment (detection bias) (C) Blinding of participants and personnel (performance bias) (C) Blinding of participa									
Test for overall effect: Z = 1.63 (P = 0.10) Fisk of bias legend. (A) Random sequence generation (selection bias) (B) Allocation conceasiment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (C) Other biases B Selective reporting (reporting bias) (G) Other biases B Total (95% CI) 2.0.74 12.9.9.2 11.93 6.32.7% -0.02 (F.7.5, 3.24) Amalraj et al. 2017a 2.9.2 0.67 12.9.9.2 11.93 6.32.7% -0.02 (F.7.5, 3.24) Total (95% CI) 4.8 and personnel (performance bias) (F) For overall effect: Z = 1.61 (P = 0.11) Biand of participants and personnel (performance bias) (B) Allocation concestment (selection bias) (C) Other biases B Total (95% CI) 4.8 and Difference Favours [experimental] Favours [control] B R Amalraj et al. 2017a 2.9.2 0.67 12.9.9.2 11.93 6.32.7% -0.08 (F.5.3, -3.63] Total (95% CI) 4.8 and personnel (performance bias) (B) Andom sequence generation (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (E) Blinding of participants and personnel performance bias) (E) Blinding of participants and personnel performance bias) (E) Blinding of participants and personnel performance bias) (E) Blinding of participants and personnel perfo		Total (95% CI)		48	3	7 100.0%	-3.91 [-8.60, 0.78]	•	
Test for overall effect: Z = 1.63 (P = 0,10)       Favours [experimental]       Favours [experim		Heterogeneity: Tau <sup>2</sup> =	16.18; Chi <sup>2</sup> = 41	36, df = 2 (F	<pre>&lt; 0.00001)</pre>	; l² = 95%			4
<ul> <li>(A) Random sequence generation (selection bias)</li> <li>(B) Alocation concentament (selection bias)</li> <li>(C) Blinding of participants and personnel (performance bias)</li> <li>(E) Blinding of outcome data (attition bias)</li> <li>(E) Incomplete outcome data (attition bias)</li> <li>(G) Other biases</li> <li>B</li> <li>Experimental Control Size (Size (Size</li></ul>		Test for overall effect:	Z = 1.63 (P = 0.	0)					,
<ul> <li>(B) Allocation conceatiment (selection bias)</li> <li>(C) Bilanding of participants and personnel (performance bias)</li> <li>(D) Bilanding of outcome assessment (detection bias)</li> <li>(E) Incomplete outcome data (attrition bias)</li> <li>(E) Selective reporting (reporting bias)</li> <li>(G) Other biases</li> <li>B</li> <li>Study or Subgroup Mean SD Total Mean SD Total Weight U. Random, 95% CI N. Random, 95% CI A B C D E F C O E</li></ul>		Risk of bias legend							
(c) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (E) Incomplete outcome assessment (geneticina bias) (F) Selective reporting (reporting bias) (G) Other biases           B         Experimental         Control         Std. Mean Difference         Std. Mean Difference         Risk of Bias									
<ul> <li>(a) Blinding of outcome assessment (detection bias) (b) Blonding of outcome assessment (detection bias) (c) Selective reporting (reporting bias) (c) Other biases</li> <li>Bestudy or Subgroup Mean SD Total Mean SD Total Weight IV. Random. 95% Cl N. Random. 95% Cl A B C D E F O Availagi et al. 2017 2.92 0.67 12 9.92 1.93 6 32.1% -0.02[0.58, 0.64] Amalagi et al. 2017 2.92 0.67 12 9.92 1.93 6 32.1% -0.00[-0.53, 3.63] Total (95% Cl) 48 37 100.0% -3.75 [-6.32, 0.81] Heterogeneity: Tau<sup>2</sup> = 15.30; Ch<sup>2</sup> = 41.43, df = 2 (P &lt; 0.00001); l<sup>2</sup> = 95% Test for overall effect: Z = 1.61 (P = 0.11) Risk of bias legend. (4) Anadom sequence generation (selection bias) (c) Blinding of outcome assessment (detection bias) (c) Blinding of outcome data (diftition bias) (c) Blinding of outcome data (diftition bias) (c) Selective reporting (reporting loss) (c) Selective reporting (reporting loss) (c</li></ul>									
(E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (G) Other biases B <u>Study or Studycoup Mean SD Total Weight UV Random, 95% Cl</u> St. Mean Difference <u>Study or Studycoup Mean SD Total Weight UV Random, 95% Cl</u> A B C D E F C Javadi et al. 2017 292 0.67 12 9.92 1.83 6 32.6% - 5.49 [-7.75, -3.24] Amalraj et al. 2017 2 0.74 12 9.92 1.83 6 32.1% - 6.06 [-5.53, -5.63] Total (95% Cl) 4 3 37 100.0% - 3.75 [-8.32, 0.81] Total (95% Cl) 2 0.7H = 41.43, df = 2 (P < 0.00001); P = 95% Test for overall effect: Z = 1.61 (P = 0.11) State of bias legendt (A) Random sequence generation (selection bias) (B) Andom sequence generation (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (E) Incomplete outcome assessment (detection bias) (E) Incomplete outcome data (dittition bias) (E) Incomplete outcome data (dittition bias) (E) Blinding of participants and personnel (performance bias) (E) Blinding of p									
(if) Selective reporting (reporting bias) (g) Other biases B <u>Study or Subgroup Mean SD Total Mean SD Total Weight IV. Random. 95% CI IV. Rand</u>					9				
(G) Other biases B Study or Study rown Mean SD Total Weight IV, Random, 95% Cl N, Random, 95% Cl A, B, C D E, F, C M, Random, 95% Cl A, B, C M, Random, 95% Cl A, B, C M, Random, 95% Cl A, B, C M, Random, 95% Cl A, A, Malaraj et al. 2017b 2, 90.2, 13.3, 6, 32.1%, -6.08 (-8.53, -3.63], -50, -50, -50, -50, -50, -50, -50, -50				naaj					
$B \\ 5 \text{ Study or Subgroup Mean SD Total Mean SD Total Weight V. Random, 95% Cl. N. R$			(reporting bidd)						
Javadi et al. 2019 1.21 1.53 24 1.24 1.66 25 $35.2\%$ -0.02 [-0.58, 0.54] Amalaj et al. 2017 2.92 0.67 12 9.92 1.93 6 $32.0\%$ -5.49 [-7.75, .3.24] Amalaj et al. 2017 2.92 0.67 12 9.92 1.93 6 $32.0\%$ -5.49 [-7.75, .3.24] Total (95% C1) 48 37 100.0% Heterogeneity: Tau <sup>2</sup> = 15 30: Ch <sup>2</sup> = 41.43, df = 2 (P < 0.00001); P = 95% Test for overall effect: Z = 1.61 (P = 0.11) Risk of bias legend (A) Random sequence generation (selection bias) (B) Aincotan conceament (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome dasessment (detection bias) (E) Incomplete outcome dasessment (detection bias) (F) Selective reporting (reporting bias)	E								
Amatraj et al. 2017b 2.92 0.67 12 9.92 1.93 6 32.6% 5.49 [-7.75, -3.24] Amatraj et al. 2017b 2.92 0.74 12 9.92 1.93 6 32.1% 6.08 [-8.53, -3.63] Total (95% CI) 48 37 100.0% -3.75 [-8.32, 0.81] Heterogeneity: Tau <sup>2</sup> = 15.30; Ch <sup>2</sup> = 41.43, df = 2 (P < 0.00001); P = 95% Test for overall effect: Z = 1.61 (P = 0.11) Risk of bias legend. (A) Random sequence generation (selection bias) (B) Alloding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (dittition bias) (F) Selective reporting (reporting bias)								IV. Random. 95% Cl	ABCDEFG
Analaj et al. 2017a 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.									<b>?</b>
Total (95% CI)       48       37       100.0%       -3.75 [-8.32, 0.81]         Heterogeneity: Tau" = 15.30; Chi <sup>2</sup> = 41.43, df = 2 (P < 0.00001); l <sup>2</sup> = 95%       -50       -25       0       25       50         Test for overall effect: Z = 1.61 (P = 0.11)       Favours [experimental]       Favours [experimental]       Favours [control]         Risk of bias legend.       (A) Random sequence generation (selection bias)       (S) Allocation concearment (selection bias)       (S) Blinding of participants and personnel (enformance bias)       (D) Blinding of outcome assessment (detection bias)         (E) Incomplete outcome data (ditrition bias)       (E) Incomplete outcome data (ditrition bias)       (F) Selective reporting (reporting bias)									
Heterogeneity: Tau <sup>2</sup> = 15 30: Ch <sup>2</sup> = 41.43, df = 2 (P < 0.00001); l <sup>2</sup> = 95% Test for overall effect: Z = 1.61 (P = 0.11) Risk of bias legend. (A) Random sequence generation (selection bias) (B) Allocation concearment (selection bias) (C) Bilinding of participants and personnel (performance bias) (D) Bilinding of outcome data (ditrition bias) (E) Incomplete outcome data (ditrition bias) (F) Selective reporting (reporting bias)		Amairaj et al. 2017b	2 0.74	12 9.92	1.93	6 32.1%	-0.08 [-8.53, -3.63]	-	
Heterogeneity: Tau <sup>2</sup> = 15 30: Ch <sup>2</sup> = 41.43, df = 2 (P < 0.00001); l <sup>2</sup> = 95% Test for overall effect: Z = 1.61 (P = 0.11) Risk of bias legend. (A) Random sequence generation (selection bias) (B) Allocation concearment (selection bias) (C) Bilinding of participants and personnel (performance bias) (D) Bilinding of outcome data (ditrition bias) (E) Incomplete outcome data (ditrition bias) (F) Selective reporting (reporting bias)		Total (95% CI)		48	3	7 100.0%	-3.75 [-8.32, 0.81]	•	
Test for overall effect: Z = 1.61 (P = 0.11)     -30 -25 - 50 -25 -25 -50			15.30; Chi <sup>2</sup> = 41	43, df = 2 (F	<pre>&lt; 0.00001)</pre>	; l <sup>2</sup> = 95%			-
Risk of bias legend.         (A) Random sequence generation (selection bias)         (B) Allocation conceaiment (selection bias)         (C) Binding of participants and personnel (performance bias)         (D) Binding of outcome assessment (detection bias)         (E) nocmplete outcome data (attrition bias)         (F) Selective reporting (reporting bias)							Favo		
<ul> <li>(A) Random sequence generation (selection bias)</li> <li>(B) Allocation conceaiment (selection bias)</li> <li>(C) Bilinding of participants and personnel (performance bias)</li> <li>(D) Bilinding of outcome assessment (detection bias)</li> <li>(E) Incomplete outcome data (attrition bias)</li> <li>(F) Selective reporting (reporting bias)</li> </ul>		Test for overall effect:	Z = 1.61 (P = 0.1				1 400	ours ferbourneural i avours feorinoil	
(b) Allocation conceatiment (selection bias) (C) Bilinding of participants and personnel (performance bias) (D) Bilinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)			Z = 1.61 (P = 0.1	.,					
<ul> <li>(C) Blinding of participants and personnel (performance bias)</li> <li>(D) Blinding of outcome assessment (detection bias)</li> <li>(E) Incomplete outcome data (attrition bias)</li> <li>(F) Selective reporting (reporting bias)</li> </ul>		Risk of bias legend	· ·	,					
(D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrilion bias) (F) Selective reporting (reporting bias)		Risk of bias legend (A) Random sequence	generation (sel	ection bias)					
(E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)		Risk of bias legend (A) Random sequence (B) Allocation conceal	generation (sel	ection bias)	ince hias)				
(F) Selective reporting (reporting bias)		Risk of bias legend (A) Random sequence (B) Allocation conceal (C) Blinding of particip	generation (seleneration to ant sand person	ection bias) ias) iel (performa					
(G) Other biases		Risk of bias legend (A) Random sequence (B) Allocation conceall (C) Blinding of particip (D) Blinding of outcom	generation (sel nent (selection t ants and person e assessment (d	ection bias) las) lel (performa etection bias					
		Risk of bias legend (A) Random sequence (B) Allocation conceall (C) Blinding of particip (D) Blinding of outcom (E) Incomplete outcom	generation (sel nent (selection t ants and person e assessment (d e data (attrition	ection bias) las) lel (performa etection bias					
		Risk of bias legend (A) Random sequence (B) Allocation conceali (C) Blinding of particip (D) Blinding of outcom (E) Incomplete outcom (F) Selective reporting	generation (sel nent (selection t ants and person e assessment (d e data (attrition	ection bias) las) lel (performa etection bias					
		Risk of bias legend (A) Random sequence (B) Allocation conceali (C) Blinding of particip (D) Blinding of outcom (E) Incomplete outcom (F) Selective reporting	generation (sel nent (selection t ants and person e assessment (d e data (attrition	ection bias) las) lel (performa etection bias					

7

	Experimental	Control		Std. Mean Difference	Std. Mean Difference	Risk of Bias
Study or Subgroup Javadi et al. 2019			tal Weight 25 17.6%	IV. Random, 95% Cl -0.06 [-0.62, 0.50]	IV, Random, 95% Cl	
Amalraj et al. 2017a		2 126.9 17.3	6 8.7%	-9.64 [-13.34, -5.95]	-	????
Amalraj et al. 2017b		2 126.9 17.3	6 8.3%	-10.10 [-13.96, -6.24]	-	?????++
Jacob et al. 2018a	20.75 5.65	8 130.75 19.57	4 7.2%	-8.67 [-13.07, -4.27]	-	????
Jacob et al. 2018b		8 130.75 19.57	4 7.0%	-8.85 [-13.33, -4.37]	-	? ? ? ? ÷ • •
Chandran et al. 2012a Chandran et al. 2012b	24.86 17.7 1 24.92 22.6 1	4 24.75 13.5 2 24.75 13.5	6 16.9% 6 16.8%	0.01 [-0.95, 0.96]	I	
Pourhabibi-Zarandi et al			6 16.8% 22 17.5%	0.01 [-0.97, 0.99] -0.95 [-1.58, -0.32]	1	
	1. LOLL 10.00 0.00 L					
Total (95% CI)	11		79 100.0%	-3.09 [-4.60, -1.58]	•	
Heterogeneity: Tau <sup>2</sup> = 3 Test for overall effect: 2	3.29; Chi <sup>2</sup> = 80.03, df = 7 (P < Z = 4.00 (P < 0.0001)	0.00001); I <sup>2</sup> = 91%		1	-100 -50 0 50 100 Favours [experimental] Favours [control]	
<ul> <li>(B) Allocation concealm</li> <li>(C) Blinding of participal</li> </ul>	ants and personnel (performan e assessment (detection bias) e data (attrition bias)	ce bias)				
В	Experimental	Control		Mean Difference	Mean Difference	Risk of Bias
Study or Subgroup	Mean SD To	al Mean SD Tot		IV. Random. 95% Cl	IV. Random. 95% Cl	ABCDEFG
Amalraj et al. 2017a			6 19.8%	-0.40 [-0.53, -0.27]		<b>?</b> ? ? ? <b>+ + +</b>
Amalraj et al. 2017b			6 19.9% 4 19.4%	-0.49 [-0.62, -0.36]	1	2 2 2 2
Jacob et al. 2018a Jacob et al. 2018b			4 19.4% 4 19.7%	-0.39 [-0.54, -0.24] -0.43 [-0.56, -0.30]	÷	2 2 2 2
Pourhabibi-Zarandi et			2 21.2%	-0.06 [-0.13, 0.01]	-	
					•	
Total (95% CI) Heterogeneity: Tau <sup>2</sup> = Test for overall effect:	0.05; Chi <sup>2</sup> = 58.82, df = 4 (P		2 100.0%	<b>-0.35 [-0.55, -0.15]</b> Fa	-2 -1 0 1 2 avours [experimental] Favours [control]	
<ul> <li>(B) Allocation conceals</li> <li>(C) Blinding of participation</li> </ul>	ants and personnel (performa le assessment (detection bias ne data (attrition bias)					
С	Experimental	Control	Mea	n Difference	Mean Difference	Risk of Bias
Study or Subgroup			eight	IV, Fixed, 95% CI	IV, Fixed, 95% CI	ABCDEFG
Amalraj et al. 2017a	24.4 5.7 12 72			0 [-68.27, -28.53]		????++
Amalraj et al. 2017b	23.8 6 12 72			0 [-68.90, -29.10]		? ? ? ? <b>+ + •</b>
Jacob et al. 2018a Jacob et al. 2018b		6 17.73 4 2 6 17.73 4 2		7 [-69.71, -34.63] 5 [-71.92, -36.98]		2 2 2 2 4 4
Jacob et al. 20160	21.10 2.09 0 70	0 11.13 4 2	0.070 =04.4	5 [-1 1.82, =30.80]	-	
Total (95% CI)	40	20 16	0.0% -51.30	[-60.59, -42.01]	•	
Heterogeneity: Chi <sup>2</sup> =	0.27, df = 3 (P = 0.97); l <sup>2</sup> =			· · · · · -	-200 -100 0 100 200	
Test for overall effect:	:: Z = 10.82 (P < 0.00001)			Favo	urs [experimental] Favours [control]	
Diels of bies is and						
Risk of bias legend	e generation (selection bias)					
	Iment (selection bias)					
	pants and personnel (perforr	nance bias)				
	ne assessment (detection bi					
	me data (attrition bias)					
(E) Incomplete outcor						

showed that there was a statistical difference between the experimental group and the control group (P<0.00001), which indicates that curcumin may decrease RF [WMD -51.30 (-60.59, -42.01)] (Figure 5C).

### 3.4.3 Adverse Events

Four (4) RCTs reported the adverse events. The result of heterogeneity analysis was I2 = 0% and P=0.93, which showed that there was no statistical heterogeneity among the 4 studies, so the fixed effects model was used. The results of Meta analysis showed that the difference between the experimental group and control group is of no statistical significance [RR 0.36 (0.11, 1.15), P=0.08] (**Figure 6**).

## 3.5 The Outcomes for OA

### 3.5.1 Efficacy Indicators

The efficacy indicators include pain (include VAS and WOMACpain), physical function and stiffness. The efficacy indicators were divided into subgroups according to the intervention methods (**Table 2**). (1) Pain: The results of Meta analysis showed that there was a statistical difference between the experimental group and the control group (VAS: P<0.0001; WOMAC-pain: P<0.00001), which indicates thatcurcuminmaydecrease VASandWOMAC-pain[VAS:SMD-2.03 (-3.03,-1.03); WOMAC-pain: SMD-0.69(-0.83,-0.55)] (Figures 7, 8).

(2) Physical function: The results of Meta analysis showed that there was a statistical difference between the experimental group and the control group (P=0.001), which indicates that curcumin may decrease WOMAC-physical function [SMD -1.65 (-2.65, -0.64)] (Figure 9).

(3) Stiffness: The results of Meta analysis showed that there was a statistical difference between the experimental group and the control group (P=0.0007), which indicates that curcumin may decrease WOMAC-stiffness [SMD -0.22 (-0.35, -0.09)] (Figure 10).

### 3.5.2 Inflammatory Indicators

The inflammatory indicators include ESR, CRP and COX-2.

(1) ESR: Two (2) RCTs reported the ESR. The result of heterogeneity analysis was I2 = 0% and P=0.41, which showed that there was no statistical heterogeneity among the 2 studies, so




TABLE 2 | The subgroup analysis of OA efficacy indicators and adverse events.

Outcomes	Subgroup			Overall effect			Hete	erogeneity t	est	Figure
		MD	95%CI	Ρ	l <sup>2</sup> (%)	Ρ	Statistical method	Studies (N)	Sample size (N)	-
VAS	Curcuma longa Extract and curcumin (C.) v.s. placebo	-1.33	[-2.23, -0.43]	P=0.004	94	P<0.0001	Random	6	431	Figure 7
	C. v.s. NSAIDs	-0.07	[-0.32, 0.19]	P=0.62	0	P=0.54	Random	2	230	
	C.+ NSAIDs v.s. NSAIDs	-9.37	[-10.45, -8.28]	P<0.0001	-	-	Random	1	160	
	C. v.s. Articular cartilage nutrition drug	-2.71	[-5.91, 0.39]	P=0.09	98	P<0.0001	Random	2	204	
WOMAC-pain	C. v.s. placebo	-0.66	[-0.88, -0.43]	P<0.0001	34	P=0.21	Fixed	4	315	Figure 8
	C. v.s. NSAIDs	0.04	[-0.18, 0.25]	P=0.72	-	-	Fixed	1	331	
	C.+ NSAIDs v.s. NSAIDs	-4.1	[-4.65, -3.55]	P<0.0001	-	-	Fixed	1	160	
	C. v.s. Articular cartilage nutrition drug	-1.33	[-1.69, -0.98]	P<0.0001	1	P=0.32	Fixed	2	152	
WOMAC-physical	C. v.s. placebo	-0.79	[-1.27, -0.31]	P=0.001	75	P=0.008	Random	4	315	Figure 9
	C. v.s. NSAIDs	0.07	[-0.14, 0.29]	p=0.51	-	-	Random	1	331	
	C.+ NSAIDs v.s. NSAIDs	-3.81	[-4.34, -3.29]	P<0.00001	-	-	Random	1	160	
	C. v.s. Articular cartilage nutrition drug	-3.1	[-4.34, -1.86]	P<0.00001	84	P=0.01	Random	2	152	
WOMAC-stiffness	C. v.s. placebo	-0.35	[-0.57, -0.12]	P=0.002	26	P=0.25	Fixed	4	315	Figure 1
	C. v.s. NSAIDs	0.05	[-0.17, 0.27]	P=0.65	-	-	Fixed	1	331	
	C.+ NSAIDs v.s. NSAIDs	-0.45	[-0.77, -0.14]	P=0.005	-	-	Fixed	1	160	
	C. v.s. Articular cartilage nutrition drug	-0.32	[-0.64, -0.00]	P=0.05	0	P=0.49	Fixed	2	152	
Adverse events	C. v.s. placebo	1.18	-0.00j [0.71, 1.94]	P=0.52	25	P=0.25	Random	8	629	Figure 1
	C. v.s. NSAIDs	0.55	[0.34, 0.88]	p=0.01	70	P=0.03	Random	3	561	
	C.+ NSAIDs v.s. NSAIDs	0.53	[0.10,	P=0.45	-	-	Random	1	160	
	C. v.s. Articular cartilage nutrition drug	0.58	2.79] [0.27, 1.24]	P=0.16	0	P=0.49	Random	2	158	

Churche an Curk manua	Experime		Cont			Std. Mean Difference	Std. Mean Difference	Risk of Bias
Study or Subgroup 1.1.1 C v.s. placebo	Mean SE	Total	viean a	D Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl	ABCDEFG
Wang et al. 2020	31.2 19.26	36	39.8 28.	49 34	7.8%	-0.35 [-0.82, 0.12]		
Jamali et al. 2020	45.2 17.8		56.6 16			-0.66 [-1.13, -0.18]		<b>AAAAAA</b>
Henrotin et al. 2019a	38 4	49	49	1 23		-3.24 [-3.98, -2.50]	+	
Henrotin et al. 2019b	37 4			1 22		-3.53 [-4.32, -2.74]	-	
Panahi et al. 2014	36 18			15 21		0.06 [-0.56, 0.68]	+	
Madhu et al. 2013a	19.48 17.84		46.03 20.			-1.35 [-1.92, -0.78]	•	
Sterzi et al. 2016	14.6 17.3		22.6 18			-0.44 [-1.00, 0.12]		••••
Subtotal (95% CI)		239		192		-1.33 [-2.23, -0.43]	•	
Heterogeneity: Tau <sup>2</sup> = 1.39	: Chi <sup>2</sup> = 100.61.	df = 6 (P	< 0.00001	: l <sup>2</sup> = 94%				
Test for overall effect: Z =								
1.1.2 C v.s. NSAIDs								
Shep et al. 2019	22 8.1			.1 69		0.00 [-0.33, 0.33]	t	
Kuptniratsaikul et al. 2009	2.7 2.5		3.1 2	.3 46		-0.17 [-0.58, 0.25]	1	
Subtotal (95% CI)		115		115	15.8%	-0.07 [-0.32, 0.19]	1	
Heterogeneity: Tau <sup>2</sup> = 0.00 Test for overall effect: Z =		= 1 (P = 0	).54); l² = (	1%				
1.1.3 C+NSAIDs v.s. NSA	IDs							
Srivastava et al. 2016 Subtotal (95% CI)	4.03 0.08	78 78	5.11 0.	14 82 82		-9.37 [-10.45, -8.28] -9.37 [-10.45, -8.28]		•••??•••
Heterogeneity: Not applica Test for overall effect: Z =		01)						
1.1.4 C v.s. Articular cart	lage nutrition of	Irug						
Madhu et al. 2013b	36.33 28.99	28 2	29.29 20.	58 24		0.27 [-0.28, 0.82]	t t	
Thomas et al. 2021	3.64 0.52		4.93 0.			-2.20 [-2.80, -1.61]		
Khanna et al. 2020	2.8 0.31		5.26 0.			-6.31 [-7.40, -5.21]	-	?????++
Subtotal (95% CI)		103	10. 10. 1 M 10. 10. 1	101	22.8%	-2.71 [-5.81, 0.39]	-	
Heterogeneity: Tau <sup>2</sup> = 7.33 Test for overall effect: Z =		df = 2 (P	< 0.00001	; I² = 98%	•			
Total (95% CI)		535		490	100.0%	-2.03 [-3.03, -1.03]	•	
Heterogeneity: Tau <sup>2</sup> = 3.28	; Chi <sup>2</sup> = 506.09,	df = 12 (F	9 < 0.0000	l); l² = 98	%		-20 -10 0 10 20	
Test for overall effect: Z =						F	avours [experimental] Favours [control]	
Test for subgroup difference	es: Chi <sup>2</sup> = 271.7	1, df = 3 (	P < 0.000	01), l² = 98	3.9%			
Risk of bias legend								
(A) Random sequence ger								
(B) Allocation concealment								
(C) Blinding of participants			nce bias)					
(D) Blinding of outcome as								
(E) Incomplete outcome da								
(F) Selective reporting (rep	orting bias)							
(G) Other biases								

Experimental Control Std. Mean Difference Mean SD Total Mean SD Total Weight IV, Fixed, 95% CI Std. Mean Difference IV, Fixed, 95% Cl Risk of Bias Study or Subgroup 1.2.1 C v.s. placebo ABCDEFG -0.72 [-1.20, -0.23] -0.93 [-1.42, -0.44] -0.40 [-0.74, -0.06] -1.02 [-1.68, -0.36] **-0.66 [-0.88, -0.43]** ..... 
 1.2.2 C v.s. NSAIDs

 Kuptniratsaikul et al. 2014
 3.25
 2.11
 171
 3.17
 1.98
 160
 41.4%

 Subtotal (95% Cl)
 171
 160
 41.4%
 0.04 [-0.18, 0.25] 0.04 [-0.18, 0.25] ...... Heterogeneity: Not applicable Test for overall effect: Z = 0.35 (P = 0.72) 
 1.2.3 C+NSAIDs v.s. NSAIDs

 Srivastava et al. 2016
 9.48
 0.17
 78
 10.16
 0.16
 82
 6.3%

 Subtotal (95% CI)
 78
 78
 82
 6.3%
 -4.10 [-4.65, -3.55] -4.10 [-4.65, -3.55] Ť Heterogeneity: Not applicable Test for overall effect: Z = 14.60 (P < 0.00001) 
 1.2.4 C v.s. Articular cartilage nutrition drug

 Thomas et al. 2021
 9.03
 1.24
 35
 10.59
 1.43
 37
 7.7%

 Khanna et al. 2020
 -7.58
 1.84
 40
 -4.73
 1.9
 40
 7.7%

 Subtotal (95% Cl)
 -77.68
 1.84
 40
 -4.75
 1.9
 40
 7.7%
 -1.15 [-1.65, -0.65] -1.51 [-2.01, -1.01] -1.33 [-1.69, -0.98] Ŧ Heterogeneity: Chi<sup>2</sup> = 1.01, df = 1 (P = 0.32);  $l^2$  = 1% Test for overall effect: Z = 7.38 (P < 0.00001) 
 Total (95% Cl)
 481
 477
 100.

 Heterogeneity: Chi<sup>2</sup> = 209.78, df = 7 (P < 0.00001); l<sup>2</sup> = 97%
 Test for subgroup differences: Chi<sup>2</sup> = 204.19, df = 3 (P < 0.00001), l<sup>2</sup> = 98.5%
 Test for subgroup differences: Chi<sup>2</sup> = 204.19, df = 3 (P < 0.00001), l<sup>2</sup> = 98.5%


 Test for address generation (selection bias)
 (A) Random sequence generation (selection bias)
 (B) Allocation concealment (selection bias)
 (C) Blinding of participants and personnel (revenues bias)
 477 100.0% -0.69 [-0.83, -0.55] -10 -5 ò 5 10 -10 -5 0 5 10 Favours [experimental] Favours [control] (u) succetton conceatment (selection bias)
 (C) Blinding of participants and personnel (performance bias)
 (D) Blinding of outcome assessment (detection bias)
 (E) incomplete outcome data (attrition bias)
 (F) Selective reporting (reporting bias)
 (G) Other biases FIGURE 8 | WOMAC-pain.

		erimental			ontrol			Std. Mean Difference	Std. Mean Difference	Risk of Bias
Study or Subgroup	Mean	SD 1	otal N	lean	SD	fotal V	Veight	IV, Random, 95% CI	IV, Random, 95% Cl	ABCDEFG
1.3.1 C v.s. placebo	200.4	404 64	20 0	700	005.40	24	10.00/	0.7514.04 0.001	-	
Wang et al. 2020	398.4			76.6 3			12.6%	-0.75 [-1.24, -0.26]		
Hashemzadeh et al. 2020	42.61	16.7			27.56		12.6%	-1.17 [-1.68, -0.67]		
Haroyan et al. 2018	4.37	9.02			12.76		12.8%	-0.25 [-0.59, 0.09]	-1	
Panahi et al. 2014 Subtotal (95% CI)	18.7	10.3	19 157	30.4	9.4		12.2% 50.2%	-1.17 [-1.84, -0.49] -0.79 [-1.27, -0.31]	•	
Heterogeneity: Tau <sup>2</sup> = 0.18	0. 0.62 - 11			001.12	- 759/	156	50.2%	-0.79 [-1.27, -0.31]	•	
Test for overall effect: Z =			(F = 0.0	<i>1</i> 00), I <sup>_</sup>	- 75%					
1.3.2 C v.s. NSAIDs										
Kuptniratsaikul et al. 2014	3.41			3.26	2.05		12.9%	0.07 [-0.14, 0.29]	t	
Subtotal (95% CI)			171			160	12.9%	0.07 [-0.14, 0.29]	1	
Heterogeneity: Not applica Test for overall effect: Z =		.51)								
1.3.3 C+NSAIDs v.s. NSA	IDs									
Srivastava et al. 2016	32.14	0.4	78 3	3.88	0.5	82	12.5%	-3.81 [-4.34, -3.29]		•••??•••
Subtotal (95% CI)			78			82	12.5%	-3.81 [-4.34, -3.29]	•	
Heterogeneity: Not applica										
Test for overall effect: Z =	14.25 (P <	0.00001)								
1.3.4 C v.s. Articular cart	ilage nutri	ion drug								
Thomas et al. 2021	32.32	2.44	35 4		3.25		12.0%	-3.76 [-4.54, -2.98]	-	
Khanna et al. 2020 Subtotal (95% CI)	-24.88	5.32	40 -1 75		5.2		12.4% 24.4%	-2.49 [-3.08, -1.90] -3.10 [-4.34, -1.86]	•	? ? ? ? ♥ ♥
Heterogeneity: Tau <sup>2</sup> = 0.68 Test for overall effect: Z =			P = 0.01	);  ² = 8	34%					
Total (95% CI)			481			477 1	00.0%	-1.65 [-2.65, -0.64]	•	
Heterogeneity: Tau <sup>2</sup> = 2.02	2: Chi <sup>2</sup> = 28			.00001	);   <sup>2</sup> = 98 <sup>4</sup>				<u> </u>	
Test for overall effect: Z =									-10 -5 0 5 10	
Test for subgroup difference			= 3 (P <	0.000	01), l² = 9	98.5%		Far	vours [experimental] Favours [control]	
Risk of bias legend										
(A) Random sequence ger	neration (se	lection bia	is)							
(B) Allocation concealment										
(C) Blinding of participants	and persor	nnel (perfo	rmance	bias)						
(D) Blinding of outcome as	sessment (	detection	bias)							
(E) Incomplete outcome da										
(F) Selective reporting (rep	orting bias									
(G) Other biases										
physical function.										

the fixed effects model was used. The results of Meta analysis showed that there was a statistical difference between the experimental group and the control group (P<0.0001), which indicates that curcumin may decrease ESR [WMD -1.00 (-1.26, -0.74)] (**Figure 11A**).

(2) CRP: Three (3) RCTs reported the CRP. The result of heterogeneity analysis was I2 = 94% and P<0.00001, which showed that there was statistical heterogeneity among the 3 studies, so the random effects model was used. The results of Meta analysis showed that there was no a statistical difference

		erimenta			Control			Std. Mean Difference		Risk of Bias
Study or Subgroup 1.4.1 C v.s. placebo	Mean	SD 1	otal	Mean	SD	Total	Weight	IV, Fixed, 95%	CI IV, Fixed, 95% CI	ABCDEFG
Wang et al. 2020	48.6	42.14	36	76.2	53.64	34	7.1%	-0.57 [-1.05, -0.09	au 🚽	
Hashemzadeh et al. 2020		1.93	36	2.94	2.04	35	7.5%	-0.15 [-0.62, 0.32		
Haroyan et al. 2018	1.58	1.7	66	1.95	1.76	68	14.1%	-0.21 [-0.55, 0.13		
Panahi et al. 2014	0.15	0.5	19	0.76		21	3.9%	-0.81 [-1.46, -0.16		
Subtotal (95% CI)			157			158	32.6%	-0.35 [-0.57, -0.12		
Heterogeneity: Chi <sup>2</sup> = 4.07,	df = 3 (P	= 0.25);	² = 26	i%						
Test for overall effect: Z = 3	.04 (P =	0.002)								
1.4.2 C v.s. NSAIDs										
Kuptniratsaikul et al. 2014	3.28			3.16	2.36	160	35.0%	0.05 [-0.17, 0.2]		
Subtotal (95% CI)			171			160	35.0%	0.05 [-0.17, 0.27	1	
Heterogeneity: Not applicat										
Test for overall effect: Z = 0	0.46 (P =	0.65)								
1.4.3 C+NSAIDs v.s. NSAI										
Srivastava et al. 2016	4.08	0.17		4.16	0.18		16.5%	-0.45 [-0.77, -0.14		••??•••
Subtotal (95% CI)			78			82	16.5%	-0.45 [-0.77, -0.14	ij 🔻	
Heterogeneity: Not applicat		0.005								
Test for overall effect: Z = 2	.84 (P =	0.005)								
1.4.4 C v.s. Articular cartil										
Thomas et al. 2021		1.32			0.84	37	7.6%	-0.21 [-0.67, 0.26		
Khanna et al. 2020	-2.31	1.35		-1.73	1.31	40	8.3%	-0.43 [-0.88, 0.01		?????+++
Subtotal (95% CI)		0.40	75	,		77	15.9%	-0.32 [-0.64, -0.00	u •	
Heterogeneity: Chi <sup>2</sup> = 0.47,			r = 0%	6						
Test for overall effect: Z = 1	.90 (P =	0.05)								
Total (95% CI)			481			477	100.0%	-0.22 [-0.35, -0.09	a	
Heterogeneity: Chi <sup>2</sup> = 14.37			1² = 5	1%					-10 -5 0 5 10	_
Test for overall effect: Z = 3									Favours [experimental] Favours [control]	
Test for subgroup difference	es: Chi² =	9.83, df	= 3 (P	= 0.02	?),   <sup>2</sup> = 6	9.5%				
Risk of bias legend										
(A) Random sequence gen			las)							
(B) Allocation concealment (C) Blinding of participants :			forma	noo hi	20)					
(D) Blinding of participants a (D) Blinding of outcome ass					15)					
<ul> <li>(E) Incomplete outcome data</li> </ul>			1 0100	,						
(F) Selective reporting (repo										
(G) Other biases		-,								
(=) = = = = = = = = = = = = = = = = = =										



between the experimental group and the control group [SMD -1.00 (-1.86, 0.42), P=0.21] (Figure 11B).

(3) COX-2 was only reported by 60, who found no significant difference in COX-2 between the diclofenac sodium group and the curcumin group (P=0.89).

### 3.5.3 Oxidative Stress Related Outcomes

The indicators related to oxidative stress include SOD, GSH, and MDA.

Two (2) RCTs reported MDA. The result of heterogeneity analysis was I2 = 94%, P<0.0001, which showed that there was statistical heterogeneity among the 2 studies, so the random effects model was used. The results of Meta analysis showed that there was a statistical difference between the experimental group and the control group (P=0.02), which indicates that curcumin may decrease MDA [WMD -2.06, (-3.80 to -0.32)]. (Figure 12).

Only Panahi et al., 2016 reported improvements in SOD and GSH and found higher serum SOD activity in the curcumin group compared to placebo (P<0.001). However, there was no


statistically significant difference in GSH levels between the curcumin group and the placebo group (P=0.064).

#### 3.5.4 Adverse Events

The subgroup analysis results were shown in **Table 2**. 49, 53, 61 and 67 claimed that no serious adverse events were observed in either the experimental group or the control group. The summary result showed a borderline difference [RR 0.74, (0.54, 1.00), P=0.05; random effect model]. (**Figure 13**). If the study increases, it may be possible to find fewer adverse events with the addition of curcumin.

### 3.6 The Outcomes for AS

Only Ahmadi et al., 2020 (62) reported on AS. They reported that 12 patients received Nanocurcumin and 12 received Placebo. They found that the AS patients in the Nanocurcumin group had significantly increased Treg cells, increased IL-10 and TGF- $\beta$  levels, and decreased IL-6 levels compared to control group. They also found that Nanocurcumin decreased the expressions



3.1.1 $C v_{a}$ , piacebo Vang ot al. 2020 14 36 18 34 145%, 0.73 [0.44, 1.23] Jamail et al. 2020 0 36 0 36 Herrofine tal. 2019a 18 49 32 5.2%, 1.56 [0.48, 5.11] Harshernzade tal. 2020 36 0 35 Not estimable Haroyan et al. 2019 10 47 3 22 5.2%, 1.56 [0.48, 5.11] Harshernzade tal. 2020 36 0 35 Not estimable Haroyan et al. 2014 3 19 4 21 41%, 0.63 [0.21, 3.24] Nakagawa et al. 2014 0 18 0 23 Not estimable Haroyan et al. 2014 3 19 4 21 41%, 0.63 [0.15, 5.67] Nakagawa et al. 2014 0 18 0 23 Not estimable Haroyan et al. 2014 3 19 2 30 2.3%, 1.00 [0.15, 6.64] Total events 54 33 Heterogeneity. Tau" = 0.1; Ch" = 5.68, df = 5 (P = 0.25); P = 25%, Test for overall effect: 2 = 0.44 (P = 0.52) 3.1.2 C v.s. NSAIDs Shep et al. 2019 9 70 26 69 11.1%, 0.34 [0.17, 0.67] Kuptinitasakul et al. 2014 65 171 65 160 20.6%, 0.77 [0.59, 1.06] Shubtotal (95% C) 26 7.67, df = 2.17 84, 92 2.9%, 0.53 [0.10, 2.78] Shubtotal (95% C) 78 2 78 4 82 2.9%, 0.53 [0.10, 2.78] Shubtotal (95% C) 78 2 78 4 82 2.9%, 0.53 [0.10, 2.78] Shubtotal (95% C) 78 2 78 4 82 2.9%, 0.53 [0.10, 2.78] Shubtotal (95% C) 78 2 78 4 82 2.9%, 0.53 [0.10, 2.78] Shubtotal (95% C) 78 2 78 4 0.03; P = 70%, Test for overall effect: Z = 0.47, df = 11 (P = 0.05); P = 70%, Test for overall effect: Z = 0.47, df = 11 (P = 0.05); P = 70%, Test for overall effect: Z = 0.47, df = 11 (P = 0.05); P = 70%, Test for overall effect: Z = 1.40 (P = 0.16) Total events 9 15 Heterogeneity. Tau" = 0.0; Ch" = 18,74, df = 11 (P = 0.07); P = 41%, Test for overall effect: Z = 1.40 (P = 0.16) Test for overall effect: Z = 1.40 (P = 0.16) Test for overall effect: Z = 1.40 (P = 0.16) Test for overall effect: Z = 1.40 (P = 0.16) Test for overall effect: Z = 1.40 (P = 0.16) Test for overall effect: Z = 1.40 (P = 0.16) Test for overall effect: Z = 1.40 (P = 0.16) Test for overall effect: Z = 1.40 (P = 0.16) Test for overall effect: Z = 1.40 (P = 0.16) Test for overall effect: Z = 1.40 (P = 0.16) Test for overall effect: Z = 1.40 (P = 0.16) Test for overall effect:	Study or Subgroup	Experime Events		Contr		Weight	Risk Ratio	Risk Ratio M-H, Random, 95% Cl	Risk of Bias A B C D E F G
Wang et al. 2020 14 38 18 34 14.5% Herrotin et al. 2019b 10 47 32 5.7% 28 20.92, 8611 Herrotin et al. 2019b 10 47 3 22 5.7% 12 82 10.92, 8611 Hashernzadeh et al. 2020 10 47 3 22 5.7% 12 82 10.92, 8611 Hashernzadeh et al. 2020 10 47 3 22 5.7% 12 82 10.92, 8611 Hashernzadeh et al. 2020 10 4 7 3 19 4 21 4.1% Not estimable Not estimabl		LYCINS	Total	- 7CH15	Total	reight		M-H, Kandolli, 3578 Cl	ADODLFG
Januar et al. 2020 Herrotin et al. 2019a Herrotin et al. 2019b Herrotin et al. 2019b Harsyn et al. 2017b Total events Harsyn et al. 2014 Herrotin et al. 2017b Herrotin et al. 2017c Herrotin et al. 2017c Herrotin et al.		14	36	18	34	14.5%	0 73 [0 44 1 23]		
Herrortin et al. 2019a 18 49 3 22 5.7% Herrortin et al. 2019b 10 47 32 25 5.7% Hardhar et al. 2020 0 38 0 35 Hardyan et al. 2016 7 66 4 68 5.2% Hardyan et al. 2016 7 6 66 4 68 5.2% Hardyan et al. 2016 7 8 66 4 68 5.2% Hardyan et al. 2016 7 8 66 4 68 5.2% Hardyan et al. 2013 2 30 2 30 2.3% Haterogenety: Tat = 0.1C; Ch <sup>2</sup> = 6.6, df = 5 (P = 0.25); P = 25% Test for overall effect: $2 = 0.64$ (P = 0.52) <b>3.1.2</b> C vs. NSADS Subtotal (65% Cl) 2 26 275 48.4% Do 25 [0.34, 0.88] <b>3.1.3</b> C vs. NSADS Subtotal (65% Cl) 2 26 275 48.4% Do 25 [0.34, 0.88] <b>3.1.3</b> C vs. NSADS Subtotal (65% Cl) 7 8 4 82 2.9% Subtotal (65% Cl) 7 8 4 82 2.9% Subtotal (65% Cl) 7 8 2 72 6 100.0% Total events 9 15 Heterogenetiy: Tat" = 0.1C; Ch <sup>2</sup> = 0.76; (P = 0.45); P = 70% Test for overall effect: $2 = -0.47$ , $df = 1 (P = 0.03); P = 70%$ Test for overall effect: $2 = -0.47$ , $df = 1 (P = 0.04); P = 70%$ Test for overall effect: $2 = -0.47$ , $df = 1 (P = 0.04); P = 70%$ Test for overall effect: $2 = -0.47$ , $df = 1 (P = 0.04); P = 70%$ Test for overall effect: $2 = -0.47$ , $df = 1 (P = 0.04); P = 70%$ Test for overall effect: $2 = -0.47$ , $df = 1 (P = 0.04); P = 70%$ Test for overall effect: $2 = -0.47$ , $df = 1 (P = 0.04); P = 70%$ Test for overall effect: $2 = -0.47$ , $df = 1 (P = 0.04); P = 70%$ Test for overall effect: $2 = -0.47$ , $df = 1 (P = 0.04); P = 0.5%$ Total events 9 15 Heterogenetiy: Tat" = 0.0; Ch <sup>2</sup> = 4.37, $df = 1 (P = 0.04); P = 0.5%$ Test for overall effect: $2 = -1.40$ , $P = 0.5$ ) Test for overall effect: $2 = -1.40$ , $P = 0.5$ ) Test for overall effect: $2 = -1.40$ , $P = 0.5$ ) Test for overall effect: $2 = -1.40$ , $P = 0.5$ ) Test for overall effect: $2 = -1.40$ , $P = 0.5$ ) Test for overall effect: $2 = -1.40$ , $P = 0.5$ ) Test for overall effect: $2 = -1.40$ , $P = 0.5$ ) Test for overall effect: $2 = -1.40$ , $P = 0.5$ ) Test for overall effect: $2 = -1.40$ , $P = 0.5$ ) Test for overall effect: $2 = -1.40$ , $P = 0.5$ ) Test for overall effect: $2 = -1.40$ , $P = 0.5$ ) Test for overall effec	0								
Hencolnel al. 2019b 10 47 3 22 5.2% 15.6 [0.48, 5.11] Hardyner al. 2018 7 66 4 68 5.2% 15.0 [0.55, 5.87] Panahi et al. 2014 7 66 4 68 5.2% 15.0 [0.55, 5.87] Panahi et al. 2014 0 18 0 23 Not estimable Machu et al. 2013 2 30 2 30 2.3% 10.0 [0.15, 6.64] Subtoal (95% CI) 3377 292 37.0% 1.18 [0.71, 1.94] Total events 5 4 34 Heterogeneity: Tar <sup>2</sup> = 0.10; Ch <sup>2</sup> = 6.66, df = 5 ( $P = 0.25$ ); $P = 25\%$ Test for overall effect: $Z = 0.64 (P = 0.57)$ Total events 5 4 34 Heterogeneity: Tar <sup>2</sup> = 0.10; Ch <sup>2</sup> = 6.76, df = 2 ( $P = 0.03$ ); $P = 25\%$ Total events 5 40 34 Heterogeneity: Tar <sup>2</sup> = 0.12; Ch <sup>2</sup> = 6.76, df = 2 ( $P = 0.03$ ); $P = 70\%$ Total events 6 7 4 82 2.9% Subtoal (95% CI) 2 78 4 82 2.9% Subtoal (95% CI) 78 4 22 2.9% Subtoal (95% CI) 78 4 22 2.9% Subtoal (95% CI) 78 4 22 2.9% Subtoal (95% CI) 78 4 30 5 30 5.0% Subtoal (95% CI) 78 4 30 5 30 5.0% Subtoal (95% CI) 78 4 30 5 30 5.0% Subtoal (95% CI) 78 4 77 1.7% Subtoal (95% CI) 78 72 72 6 100.0% Total events 2 4 Heterogeneity: Tar <sup>2</sup> = 0.07; $P = 0.45$ ) <b>3.14</b> C v.s. Articular cartiling nutrition drug Machu et al. 2013 4 30 5 30 5.0% Subtoal (95% CI) 78 72 72 6 100.0% Total events 1 45 177 Heterogeneity: Tar <sup>2</sup> = 0.07; $P = 0.45$ ) <b>3.14</b> C v.s. Articular cartiling nutrition fung Machu et al. 2013 4 30 5 30 5.0% Subtoal (95% CI) 78 72 72 6 100.0% Total events 1 45 177 Heterogeneity: Tar <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.47, df = 1 ( $P = 0.07$ ); $P = 41\%$ Total events 145 177 Heterogeneity: Tar <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.47, df = 1 ( $P = 0.07$ ); $P = 41\%$ Total events 145 177 Heterogeneity: Tar <sup>2</sup> = 0.00; Ch <sup>2</sup> = 3.4, df = 3 ( $P = 0.07$ ); $P = 41\%$ Heterogeneity: Tar <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.47, df = 1 ( $P = 0.07$ ); $P = 41\%$ Heterogeneity: Tar <sup>2</sup> = 0.00; Ch <sup>2</sup> = 3.4, df = 3 ( $P = 0.07$ ); $P = 41\%$ Heterogeneity: Tar <sup>2</sup> = 0.00; Ch <sup>2</sup> = 3.4, df = 3 ( $P = 0.07$ ); $P = 41\%$ Heterogeneity: Tar <sup>2</sup> = 0.00; Ch <sup>2</sup> = 3.4, df = 3 ( $P = 0.01$ ); $P = 41\%$ Heterogeneity: Tar <sup>2</sup> = 0.00; Ch <sup>2</sup> = 3.4, df = 3 ( $P = 0.01$ ); $P = 41\%$ Heterogeneity: Tar <sup>2</sup> = 0.00; Ch						5.7%		<b>—</b>	
Hashemizadeh et al. 2020 0 36 0 35 Mole estimable Harvynen et al. 2018 7 66 4 68 5.2% No estimable Marvyne et al. 2014 3 19 4 21 4.1% 0.83 [0.21, 3.24] Nakagwa et al. 2014 0 18 0 23 No estimable Machu et al. 2013 2 30 2 30 2.3% 1.00 [0.15, 6.64] Subtotal [95% C] 337 292 37.0% 1.18 [0.71, 1.94] Total events 54 3 4 Heterogenely: Tau" = 0.01 (C PH = 6.66, df = 5 (P = 0.25); P = 25% Test for overall effect: Z = 0.46 (P = 0.52) 3.1.2 C v.s. NSAIDS Subtotal [95% C] 2 76 4 62 2.75 (4 - 0.03); P = 70% Total events 80 124 Heterogenely: Tau" = 0.12; C PH = 6.76, df = 2 (P = 0.03); P = 70% Total events 80 124 Heterogenely: Tau" = 0.12; C PH = 6.76, df = 2 (P = 0.03); P = 70% Total events 80 124 Heterogenely: Tau" = 0.12; C PH = 6.76, df = 2 (P = 0.03); P = 70% Total events 2 4 Heterogenely: Tau" = 0.12; C PH = 6.76, df = 2 (P = 0.03); P = 70% Total events 2 4 Heterogenely: Tau" = 0.12; C PH = 6.76, df = 2 (P = 0.03); P = 70% Total events 2 4 Heterogenely: Tau" = 0.12; C PH = 0.67, df = 2 (P = 0.03); P = 70% Total events 2 4 Heterogenely: Tau" = 0.02; C PH = 0.45); P = 0.03; P = 70% Total events 2 4 Heterogenely: Tau" = 0.02; C PH = 0.45); P = 0.03; P = 70% Total events 2 4 Heterogenely: Tau" = 0.00; C PH = 0.45, df = 1 (P = 0.03); P = 70% Total events 2 4 Heterogenely: Tau" = 0.00; C PH = 0.45, df = 2 (P = 0.03); P = 0% Test for overall effect: Z = 0.76 (P = 0.45); P = 0.% Test for overall effect: Z = 1.40 (P = 0.05); P = 2.75 10.0% Total events 9 15 Heterogenely: Tau" = 0.00; C PH = 0.47, df = 1 (P = 0.49); P = 0% Test for overall effect: Z = 1.40 (P = 0.05) Test for overall effect: Z = 1.40 (P = 0.05) Test for overall effect: Z = 1.40 (P = 0.05); P = 0.45); P = 0.45; H = 11 (P = 0.07); P = 4.1% Est for overall effect: Z = 1.40 (P = 0.05) Test for overall effect: Z = 1.40 (P = 0.05) Test for overall effect: Z = 1.40 (P = 0.05) Test for overall effect: Z = 1.40 (P = 0.05) Test for overall effect: Z = 1.40 (P = 0.05) Test for overall effect: Z = 1.40 (P = 0.05) Test for overall									
Haroyan et al. 2016 Pranshi et al. 2014 Pranshi et al. 2014 Nakagwa et al. 2014 Subtoral (6% Ci) Subtoral (6% Ci) Subto						0.270			
Panami et al. 2014 3 19 4 21 4.1% 0.83 [0.21, 3.24] Madaguare at al. 2014 0 16 8 0 23 Madhu et al. 2013a 2 30 2 3% 100 [0.15, 6.64] Subtotal (9% C) 337 222 37.0% 1.18 [0.71, 1.94] Total events 54 34 Heterogeneity: Tau" = 0.012 ( $H^{2} = 6.6, df = 5 (P = 0.25); P = 25\%$ Test for overall effect: $Z = 0.84 (P = 0.52)$ 3.1.2 C v.s. NSAIDS Shep et al. 2019 9 70 26 69 11.1% O.34 [0.17, 0.67] O.59 [0.32, 0.76] O.59 [0.32, 0.76] O.79 [0.59, 1.66] O.79 [0.59, 1.66] J.12 C v.s. NSAIDS Shep et al. 2019 9 70 26 69 11.1% O.34 [0.17, 0.67] O.79 [0.59, 1.66] O.79 [0.59, 1.66] O.79 [0.59, 1.66] O.53 [0.10, 2.79] O.53 [0.10, 2						5.2%			
Nakagawa et al. 2014 0 18 0 23 Not estimable Nakagawa et al. 2014 0 18 0 23 Not estimable Not estimable N									
Madmuter ial. 2013a 2 30 2 30 2.3% Subtotal (9% C) 337 292 37.0% 1.0 ( $0.15, 6.64$ ] 1.18 ( $0.71, 1.94$ ] Total events 54 34 Heterogeneity: Tau <sup>2</sup> = 0.10; Chi <sup>2</sup> = 6.66, df = 5 (P = 0.25); P = 25% Test for overall effect. Z = 0.64 (P = 0.52) 3.1.2 C v.s. NSAIDS Shep et al. 2019 9 70 26 69 11.1% (Lyphritrastakut et al. 2016 16 45 33 46 16.7% (Lyphritrastakut et al. 2016 55 171 65 160 20.6% Subtotal (9% C) 286 275 48.4% 1.18 ( $0.71, 0.67$ ] Subtotal (9% C) 286 275 48.4% 1.18 ( $0.71, 0.67$ ] Subtotal (9% C) 78 4 82 2.9% Subtotal (9% C) 78 51 10 47 6.7% Heterogeneity: Tau <sup>2</sup> = 0.0; Chi <sup>2</sup> = 0.47, df = 1 (P = 0.49); P = 0% Test for overall effect. Z = 0.76 (P = 0.47, df = 1 (P = 0.49); P = 0% Total events 45 15 10 47 6.7% Subtotal (9% C) 78 2 726 100.0% Total events 45 177 Heterogeneity: Tau <sup>2</sup> = 0.0; Chi <sup>2</sup> = 0.47, df = 1 (P = 0.49); P = 0% Test for overall effect. Z = 1.98 (P = 0.5) Total events 45 177 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.47, df = 1 (P = 0.49); P = 0% Test for overall effect. Z = 1.98 (P = 0.5) Total events 45 177 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.53 (P = 0.14); P = 0.47% Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.53 (P = 0.14); P = 0.47% Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.53 (P = 0.14); P = 0.47% Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14); P = 44.7% Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14); P = 44.7% Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14); P = 44.7% Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14); P = 44.7% Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14); P = 44.7% Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14); P = 44.7% Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14); P = 44.7% Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14); P = 44.7% Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14); P = 44.7% Heterog									? 🕂 ? ? 🕂 🖶 🛑
Subtotal (95% CI) 337 292 37.0% 1.18 [0.71, 1.94] Total events 54 34 Heterogeneity: Tau <sup>2</sup> = 0.10; Ch <sup>2</sup> = 6.66, df = 5 (P = 0.25); P = 25% Test for overall effect: $Z = 0.64$ (P = 0.52) 3.1.2 C v.s. NSADs Subtotal (95% CI) 2 26 69 11.1% 0.34 [0.17, 0.67] (uphritasaku et al. 2019 9 70 26 69 11.1% 0.55 [0.32, 2.76] Subtotal (95% CI) 2 286 275 48.4% 0.55 [0.34, 0.88] (uphritasaku et al. 2019 2 78 4 82 2.9% Subtotal (95% CI) 78 82 2.9% Subtotal (95% CI) 78 82 2.9% Cotal events 80 124 Heterogeneity: Tau <sup>2</sup> = 0.76 (P = 0.45) 3.1.3 C+NSAIDs × s. NSAIDs Strustava et al. 2016 2 78 4 82 2.9% Subtotal (95% CI) 78 82 2.9% Cotal events 2 4 Heterogeneity: Total events 2 4 Heterogeneity: Total events 9 15 Heterogeneity: Total = 0.76 (P = 0.45) 3.1.4 C v.s. Articular cardiage nutrition drug Machu et al. 2016 4 30 5 30 5.0% Cotal events 9 15 Heterogeneity: Tau <sup>2</sup> = 0.09; Ch <sup>2</sup> = 1.74, df = 1 (P = 0.49); P = 0% Test for overall effect: Z = 1.90 (P = 0.14), P = 44.7% Total events 19 15 Heterogeneity: Tau <sup>2</sup> = 0.09; Ch <sup>2</sup> = 1.74, df = 1 (P = 0.07); P = 41% Test for overall effect: Z = 1.90 (P = 0.16) Total events 19 15 Heterogeneity: Tau <sup>2</sup> = 0.09; Ch <sup>2</sup> = 1.74, df = 1 (P = 0.07); P = 41% Test for overall effect: Z = 1.90 (P = 0.16) Total events 145 177 Heterogeneity: Tau <sup>2</sup> = 0.09; Ch <sup>2</sup> = 1.74, df = 1 (P = 0.07); P = 41% Test for overall effect: Z = 1.90 (P = 0.16) Total (95% CI) 782 726 100.0% Total events 145 177 Heterogeneity: Tau <sup>2</sup> = 0.09; Ch <sup>2</sup> = 1.74, df = 1 (P = 0.07); P = 41% Test for overall effect: Z = 1.90 (P = 0.16) Total (95% CI) 782 726 100.0% Total events 145 177 Heterogeneity: Tau <sup>2</sup> = 0.09; Ch <sup>2</sup> = 1.74, df = 3 (P = 0.14), P = 44.7% Risk of bias leggend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Binding of participants and personnel (performance bias) (D) Binding of participants and personnel (performance bias) (D) Binding of participants and personnel (performance bias) (D) Binding of participants and personne						2.3%			
Total events $54$ $34$ Heterogeneity: Tau <sup>2</sup> = 0.10; Ch <sup>2</sup> = 6.66, df = 5 (P = 0.25); P = 25% Test for overall effect: Z = 0.64 (P = 0.52) <b>3.1.2 C v.s. NSAIDs</b> Shep et al. 2019 9 70 26 69 11.1% (Luphritasiaku et al. 2019 16 45 33 46 16.7% (Luphritasiaku et al. 2014 55 171 65 160 20.6% Subtotal (9% Cl) 286 275 48.4% Total events 80 124 Heterogeneity: Tau <sup>2</sup> = 0.10; Ch <sup>2</sup> = 6.76, df = 2 (P = 0.03); P = 70% Test for overall effect: Z = 2.49 (P = 0.01) <b>3.1.3 C+NSAIDs</b> v.s. NSAIDs Srivastava et al. 2016 2 78 4 82 2.9% Subtotal (9% Cl) 78 62 2.9% Subtotal (9% Cl) 78 62 2.9% Subtotal (9% Cl) 78 63 2.9% Subtotal (9% Cl) 78 61 77 11.7% O.53 [0.10, 2.79] O.53 [0.10, 2.79] O.54 [0.27, 124] O.55 [0.27, 1.24] O.55		-		-				◆	
Heterogeneity: Tau <sup>2</sup> = 0.10; Ch <sup>2</sup> = 5.66, df = 5 (P = 0.25); P = 25% Test for overall effect: Z = 0.64 (P = 0.52) 3.1.2 C v.s. NSADs Shep et al. 2019 9 70 26 69 11.1% Kuphiritaskuk et al. 2009 16 45 33 46 16.7% Kuphiritaskuk et al. 2009 17 26 62 275 48.4% O.55 [0.32, 0.76] Subtotal (95% Cl) 2266 275 48.4% O.55 [0.34, 0.88] Atterogeneity: Tau <sup>2</sup> = 0.12; Ch <sup>2</sup> = 6.76, df = 2 (P = 0.03); P = 70% Test for overall effect: Z = 2.49 (P = 0.01) 3.1.3 C+NSAIDs v.s. NSADs Strustata (95% Cl) 78 4 82 2.9% Subtotal (95% Cl) 78 10 47 6.7% Data events 9 15 Heterogeneity: Tau <sup>2</sup> = 0.0; Ch <sup>2</sup> = 0.47, df = 1 (P = 0.49); P = 0% Test for overall effect: Z = 1.40 (P = 0.49); P = 0% Test for overall effect: Z = 1.40 (P = 0.49); P = 0% Test for overall effect: Z = 1.40, df = 1 (P = 0.07); P = 41% Test for overall effect: Z = 1.40, df = 1 (P = 0.07); P = 44.7% Risk of bas legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (E) Incomplete outcome data (attition bias) (F) Sective reporting (reporting bias)		54		34				r	
Shep et al. 2019 9 70 26 69 11.1% 0.34 [0.17, 0.67] Kuptinitatsakul et al. 2009 16 45 33 46 16.7% 0.50 [0.32, 0.76] Kuptinitatsakul et al. 2019 226 275 48.4% 0.55 [0.34, 0.88] Subtotal (95% CI) 226 275 48.4% 0.55 [0.34, 0.88] Total events 80 124 Heterogeneity: Tau <sup>2</sup> = 0.12; Chi <sup>2</sup> = 6.76, df = 2 ( $P = 0.03$ ); $P = 70\%$ Test for overall effect: $Z = 2.49$ ( $P = 0.01$ ) 3.1.3 C+NSAIDs v.s. NSAIDs Sirvastava et al. 2016 2 78 4 82 2.9% 0.53 [0.10, 2.79] Total events 2 4 Heterogeneity: Not applicable Test for overall effect: $Z = 0.76$ ( $P = 0.45$ ) 3.1.4 C v.s. Articular cartilage nutrition drug Madhu et al. 2013 4 30 5 30 5.0% Lapresti et al. 2021 5 51 10 47 6.7% Usatoral (95% CI) 782 726 100.0% Total events 9 15 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.47, df = 1 ( $P = 0.49$ ); $P = 0\%$ Test for overall effect: $Z = 1.40$ ( $P = 0.7$ , $df = 1 (P = 0.49$ ); $P = 0\%$ Test for overall effect: $Z = 1.40$ ( $P = 0.7$ , $df = 11 (P = 0.49); P = 0\%Test for overall effect: Z = 1.40 (P = 0.7); P = 41\%Test for overall effect: Z = 1.40 (P = 0.7); P = 44.7\%Risk of bias legend.(A) Random sequence generation (selection bias)(B) Allocation concealment (selection bias)(C) Blinding of outcome assessment (detection bias)(D) Blinding of outcome data (attrition bias)(F) Selective reporting (reporting bias)(F) Selective reporting reporting bias)$	Heterogeneity: Tau <sup>2</sup> = 0.10;	Chi <sup>2</sup> = 6.66		P = 0.25	); I² = 2	5%			
Kupiniratsakul et al. 2009       16       45       33       46       16.7%       0.50       0.32, 0.76]         Kupiniratsakul et al. 2014       55       171       65       160       20.6%       0.79       (0.59, 1.06]         Subtotal (95% Cl)       286       275       48.4%       0.55       (0.3, 106)         Total events       80       124         Heterogeneity: Tar <sup>2</sup> 0.12; Ch <sup>2</sup> = 6.76, df = 2 (P = 0.03); P = 70%       78       82       2.9%       0.53       (0.10, 2.79)         Stubtotal (95% Cl)       78       82       2.9%       0.53       (0.10, 2.79)       0.53       (0.10, 2.79)         Total events       2       4       4       30       5       30       5.0%       0.53       (0.10, 2.79)         Total events       2       4       30       5       30       5.0%       0.80       (0.24, 2.69)         Lopresti et al. 2013b       4       30       5       30       5.0%       0.80       (0.24, 2.69)         Lopresti et al. 2017       5       51       10       47       6.7%       0.46       (0.17, 1.25)         Subtotal (95% Cl)       782       726       100.0%       0.74       0.54       1.00]	3.1.2 C v.s. NSAIDs								
$\begin{array}{c} \text{Notinitiatial of et al. 2010} & \text{if } $									
Subtotal (95% Cl) 286 275 48.4% 0.55 [0.34, 0.88] Total events 80 124 Heterogeneity: Tau <sup>2</sup> = 0.12; Chi <sup>2</sup> = 6.76, df = 2 (P = 0.03); P = 70% Test for overall effect: Z = 2.49 (P = 0.01) 3.1.3 C+NSAIDs v.s. NSAIDs Srivastava et al. 2016 2 78 4 82 2.9% 0.53 [0.10, 2.79] Subtotal (95% Cl) 78 82 2.9% 0.53 [0.10, 2.79] Total events 2 4 Heterogeneity: Not applicable Test for overall effect: Z = 0.76 (P = 0.45) 3.1.4 C v.s. Articular cartilage nutrition drug Madhu et al. 2013b 4 30 5 30 5.0% 0.80 [0.24, 2.69] Subtotal (95% Cl) 81 77 11.7% 0.58 [0.27, 1.24] Total events 9 15 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.47, df = 1 (P = 0.49); I <sup>2</sup> = 0% Test for overall effect: Z = 1.40 (P = 0.16) Total (95% Cl) 782 726 100.0% Total events 145 177 Heterogeneity: Tau <sup>2</sup> = 0.09; Chi <sup>2</sup> = 18.74, df = 11 (P = 0.07); I <sup>2</sup> = 41% Test for overall effect: Z = 1.99 (P = 0.05) Test for subgroup differences: Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14), I <sup>2</sup> = 41.7% Risk of bias legand. (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (E) Encomplete outcome data (attrition bias) (F) Selective reporting (tropyorting bias)								-	
Heterogeneity: Tau <sup>2</sup> = 0.12; Chi <sup>2</sup> = 6.76, df = 2 (P = 0.03); l <sup>2</sup> = 70% Test for overall effect: $Z = 2.49$ (P = 0.01) 3.1.3 C+NSAIDs v.s. NSAIDs Srivastava et al. 2016 2 78 4 82 2.9% 0.53 [0.10, 2.79] Subtotal (9% Cl) 78 62 2.9% 0.53 [0.10, 2.79] Total events 2 4 Heterogeneity: Not applicable Test for overall effect: $Z = 0.76$ (P = 0.45) 3.1.4 C v.s. Articular cartilage nutrition drug Madhu et al. 2013 4 30 5 30 5.0% 0.80 [0.24, 2.69] Lopresti et al. 2021 5 51 10 47 6.7% 0.46 [0.17, 1.25] Subtotal (95% Cl) 81 77 11.7% 0.58 [0.27, 1.24] Total events 9 15 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.47, df = 1 (P = 0.49); l <sup>2</sup> = 0.% Test for overall effect: $Z = 1.40$ (P = 0.46) Total (95% Cl) 782 726 100.0% Total events 145 177 Heterogeneity: Tau <sup>2</sup> = 0.09; Chi <sup>2</sup> = 18.74, df = 11 (P = 0.49); l <sup>2</sup> = 41% Test for overall effect: $Z = 1.40$ (P = 0.16) Total (95% Cl) 782 726 100.0% Total events 145 177 Heterogeneity: Tau <sup>2</sup> = 0.09; Chi <sup>2</sup> = 18.74, df = 11 (P = 0.49); l <sup>2</sup> = 41% Test for overall effect: $Z = 1.90$ (P = 0.16) Total (95% Cl) 782 726 100.0% Total events 145 177 Heterogeneity: Tau <sup>2</sup> = 0.09; Chi <sup>2</sup> = 15.43, df = 3 (P = 0.14), l <sup>2</sup> = 44.7% <u>Rike of bias legrend</u> (A) Random sequence generation (selection bias) (B) Allocation concealment (election bias) (C) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)		55		65				•	
Test for overall effect: $Z = 2.49 (P = 0.01)$ 3.1.3 C+NSAIDs v.s. NSAIDs Srivastava et al. 2016 2 78 4 82 2.9% 0.53 [0.10, 2.79] Subtotal (95% Cl) 78 82 2.9% 0.53 [0.10, 2.79] Total events 2 4 Heterogeneity: Not applicable Test for overall effect: $Z = 0.76 (P = 0.45)$ 3.1.4 C v.s. Articular cartilage nutrition drug Madhu et al. 2013 4 30 5 30 5.0% 0.80 [0.24, 2.69] Madhu et al. 2013 5 51 10 47 6.7% 0.46 [0.17, 1.25] Subtotal (95% Cl) 81 77 11.7% 0.58 [0.27, 1.24] Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.47, df = 1 (P = 0.49); P = 0% Test for overall effect: $Z = 1.40 (P = 0.16)$ Total events 9 15 Heterogeneity: Tau <sup>2</sup> = 0.09; Ch <sup>2</sup> = 15.74, df = 1 (P = 0.49); P = 0% Test for overall effect: $Z = 1.99 (P = 0.05)$ Test for subgroup differences: Ch <sup>2</sup> = 5.43, df = 3 (P = 0.14), P = 44.7% Risk of bias leardd. (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (F) Selective reporting (reporting bias)	Total events	80		124					
Srivastava et al. 2016 2 78 4 82 2.9% 0.53 [0.10, 2.79] Subtotal (95% CI) 78 82 2.9% 0.53 [0.10, 2.79] Total events 2 4 Heterogeneity: Not applicable Test for overall effect: $Z = 0.76 (P = 0.45)$ 3.1.4 C v.s. Articular cartilage nutrition drug Madhu et al. 2013 5 51 10 47 6.7% 0.46 [0.17, 1.25] Subtotal (95% CI) 81 77 11.7% 0.58 [0.27, 1.24] Total events 9 15 Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.47, df = 1 (P = 0.49); l <sup>2</sup> = 0% Test for overall effect: $Z = 1.40 (P = 0.46)$ Total events 145 177 Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 1.74, df = 11 (P = 0.07); l <sup>2</sup> = 41% Test for overall effect: $Z = 1.99 (P = 0.05)$ Test for subgroup differences: Ch <sup>2</sup> = 5.43, df = 3 (P = 0.14), l <sup>2</sup> = 44.7% (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)				P = 0.03	);  ² = 7	0%			
Subtrat (95% Cl) 78 82 2.9% 0.53 [0.10, 2.79] Total events 2 4 Heterogeneity: Not applicable Test for overall effect: $Z = 0.76$ (P = 0.45) 3.1.4 C v.s. Articular cartilage nutrition drug Madhu et al. 2013b 4 30 5 30 5.0% 0.80 [0.24, 2.69] Lopresti et al. 2021 5 51 10 47 6.7% 0.46 [0.17, 1.25] Subtotal (95% Cl) 81 77 11.7% 0.58 [0.27, 1.24] Total events 9 15 Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.47, df = 1 (P = 0.49); l <sup>2</sup> = 0% Test for overall effect: $Z = 1.40$ (P = 0.16) Total events 145 177 Heterogeneity: Tau <sup>2</sup> = 0.09; Ch <sup>2</sup> = 18.74, df = 11 (P = 0.07); l <sup>2</sup> = 41% Test for overall effect: $Z = 1.99$ (P = 0.05) Test for subgroup differences: Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14), l <sup>2</sup> = 44.7% Risk of bias legend (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of participants and personnel (performance bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)	3.1.3 C+NSAIDs v.s. NSAI	Ds							
Total events 2 4 Heterogeneity: Not applicable Test for overall effect: Z = 0.76 (P = 0.45) 3.1.4 C v.s. Articular cartilage nutrition drug Machu et al. 2013b 4 30 5 30 5.0% 0.80 [0.24, 2.69] Lopresti et al. 2021 5 51 10 47 6.7% 0.46 [0.17, 1.25] Subtotal (95% Cl) 61 77 11.7% 0.58 [0.27, 1.24] Total events 9 15 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.47, df = 1 (P = 0.49); l <sup>2</sup> = 0% Test for overall effect: Z = 1.90 (P = 0.16) Total events 145 177 Heterogeneity: Tau <sup>2</sup> = 0.09; Chi <sup>2</sup> = 1.74, df = 11 (P = 0.07); l <sup>2</sup> = 41% Test for overall effect: Z = 1.99 (P = 0.05) Test for subgroup differences: Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14), l <sup>2</sup> = 44.7% Risk of bias legand. (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome atsa (attrition bias) (F) Selective reporting (reporting bias)		2		4					•••??•••
Heterogeneity: Not applicable Test for overall effect: $Z = 0.76 (P = 0.45)$ 3.1.4 C v.s. Articular cartilage nutrition drug Madhu et al. 2013b 4 30 5 30 5.0% 0.80 [0.24, 2.69] Lopresti et al. 2021 5 51 10 47 6.7% 0.46 [0.17, 1.25] Subtotal (95% CI) 81 77 11.7% 0.58 [0.27, 1.24] Total events 9 15 Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.47, df = 1 (P = 0.49); l <sup>2</sup> = 0% Test for overall effect: $Z = 1.40 (P = 0.16)$ Total events 145 177 Heterogeneity: Tau <sup>2</sup> = 0.09; Chi <sup>2</sup> = 0.43, df = 1 (P = 0.49); l <sup>2</sup> = 41% Test for overall effect: $Z = 1.99 (P = 0.05)$ Test for subgroup differences: Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14), l <sup>2</sup> = 44.7% Risk of bias legend! (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (B) Allocation concealment (selection bias) (C) Blinding of outcome assessment (detection bias) (E) Incomplete outcome data (attrition bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)		0	10		02	2.9%	0.55 [0.10, 2.79]		
Madhu et al. 2013b       4       30       5       30       5.0%       0.80 [0.24, 2.69]         Lopresti et al. 2021       5       51       10       47       6.7%       0.46 [0.17, 1.25]         Subtotal (95% Cl)       81       77       11.7%       0.58 [0.27, 1.24]       ••••••••••••••••••••••••••••••••••••	Heterogeneity: Not applicab	le	5)	4					
Lopresti et al. 2021 5 51 10 47 6.7% 0.46 $[0.17, 1.25]$ Subtotal (95% Cl) 81 77 11.7% 0.58 $[0.27, 1.24]$ Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.47, df = 1 (P = 0.49); P = 0% Test for overall effect: Z = 1.40 (P = 0.16) Total events 145 177 Heterogeneity: Tau <sup>2</sup> = 0.09; Ch <sup>2</sup> = 18.74, df = 11 (P = 0.07); P = 41% Test for overall effect: Z = 1.99 (P = 0.05) Test for subgroup differences: Ch <sup>2</sup> = 5.43, df = 3 (P = 0.14), P = 44.7% Risk of bias legend. (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome data (attrition bias) (E) Incomplete outcome data (attrition bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)	3.1.4 C v.s. Articular cartil	age nutritio	on drug						
Subtotal (95% Cl)       81       77       11.7%       0.58 [0.27, 1.24]         Total events       9       15         Heterogeneity: Tau <sup>2</sup> = 0.00; Ch <sup>2</sup> = 0.47, df = 1 (P = 0.49); l <sup>2</sup> = 0%       0.74 [0.54, 1.00]         Total (95% Cl)       782       726       100.0%         Total events       145       177         Heterogeneity: Tau <sup>2</sup> = 0.09; Ch <sup>2</sup> = 1.874, df = 11 (P = 0.07); l <sup>2</sup> = 41%       0.001       0.1       1       10       1000         Test for overall effect: Z = 1.99 (P = 0.05)       rest for subgroup differences: Ch <sup>2</sup> = 5.43, df = 3 (P = 0.14), l <sup>2</sup> = 44.7%       Favours [experimental]       Favours [control]         Risk of bias legend.       (A) Random sequence generation (selection bias)       (B) Allocation concealment (selection bias)       (B) Allocation concealment (selection bias)       (C) Blinding of participants and personnel (performance bias)         (D) Blinding of outcome data (attrition bias)       (F) Incomplete outcome data (attrition bias)       (F) Selective reporting (reporting bias)	Madhu et al. 2013b	4	30	5	30	5.0%	0.80 [0.24, 2.69]		
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.47, df = 1 (P = 0.49); l <sup>2</sup> = 0% Test for overall effect: Z = 1.40 (P = 0.16) Total events 145 177 Heterogeneity: Tau <sup>2</sup> = 0.09; Chi <sup>2</sup> = 18.74, df = 11 (P = 0.07); l <sup>2</sup> = 41% Test for overall effect: Z = 1.99 (P = 0.05) Test for subgroup differences: Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14), l <sup>2</sup> = 44.7% <u>Risk of bias legend</u> (A) Random sequence generation (selection bias) (B) Allocation concealment (selection bias) (C) Blinding of participants and personnel (performance bias) (D) Blinding of outcome data (attrition bias) (E) Incomplete outcome data (attrition bias) (F) Selective reporting (reporting bias)		5		10			0.46 [0.17, 1.25]	•	
Test for overall effect: Z = 1.40 (P = 0.16)         Total (95% Cl)       782       726       100.0%       0.74 [0.54, 1.00]         Total events       145       177         Heterogeneity: Tau <sup>2</sup> = 0.09; Chi <sup>2</sup> = 18.74, df = 11 (P = 0.07); l <sup>2</sup> = 41%       0.001       0.1       1       10       1000         Test for overall effect: Z = 1.99 (P = 0.05)       Favours [experimental]       Favours [control]       Favours [control]         Risk of bias legend.       (A) Random sequence generation (selection bias)       (B) Allocation concealment (selection bias)       Favours [experimental]       Favours [control]         (C) Blinding of participants and personnel (pefortmance bias)       (C) Blinding of outcome data (attrition bias)       (F) Selective reporting (reporting bias)       (F) Selective reporting (reporting bias)		•							
Total events       145       177         Heterogeneity: Tau <sup>2</sup> = 0.09; Ch <sup>2</sup> = 18.74, df = 11 (P = 0.07); l <sup>2</sup> = 41%       0.001       0.1       1000         Test for overall effect: Z = 1.99 (P = 0.05)       Favours [experimental]       Favours [control]         Risk of bias legend       (A) Random sequence generation (selection bias)       (B) Allocatino concealment (selection bias)       Favours [experimental]       Favours [control]         (B) Allocatino concealment (selection bias)       (C) Blinding of outcome assessment (detection bias)       (E) Incomplete outcome data (attrition bias)       (F) Selective reporting (reporting bias)         (F) Selective reporting (reporting bias)       (E)       (F) Selective reporting frequenting bias)       (F) Selective reporting frequenting bias)				P = 0.49	); I² = 0	%			
Heterogeneity: Tau <sup>2</sup> = 0.09; Chi <sup>2</sup> = 18.74, df = 11 (P = 0.07); l <sup>2</sup> = 41% <ul> <li>Image: tor overall effect: Z = 1.99 (P = 0.05)</li> <li>Favours [experimental]</li> <li>Favours [control]</li> </ul> Test for subgroup differences: Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14), l <sup>2</sup> = 44.7%       Favours [experimental]       Favours [control]         Risk of bias legend       (A) Random sequence generation (selection bias)       (B) Allocation concealment (selection bias)       (C) Blinding of participants and personnel (performance bias)       (D) Blinding of outcome assessment (detection bias)       (E) Incomplete outcome data (attrition bias)       (F) Selective reporting (reporting bias)       (F) Selective reporting (reporting bias)       (F) Selective reporting (reporting bias)       (F) Selective reporting function bias	Total (95% CI)		782		726	100.0%	0.74 [0.54, 1.00]	◆	
Test for overall effect: Z = 1.99 (P = 0.05)     0.01     0.1     10     1000       Test for subgroup differences: Chi <sup>2</sup> = 5.43, df = 3 (P = 0.14), l <sup>2</sup> = 44.7%     Favours [experimental]     Favours [control]       (A) Random sequence generation (selection bias)     (B) Allocation concealment (selection bias)     (C) Blinding of participants and personnel (performance bias)       (D) Blinding of outcome assessment (detection bias)     (E) Incomplete outcome data (attrition bias)     (F) Selective reporting (reporting bias)									
<ul> <li>(A) Random sequence generation (selection bias)</li> <li>(B) Allocation concealment (selection bias)</li> <li>(C) Blinding of participants and personnel (performance bias)</li> <li>(D) Blinding of outcome assessment (detection bias)</li> <li>(E) Incomplete outcome data (attrition bias)</li> <li>(F) Selective reporting (reporting bias)</li> </ul>	Test for overall effect: Z = 1 Test for subgroup difference	.99 (P = 0.0	5)						000
<ul> <li>(B) Allocation concealment (selection bias)</li> <li>(C) Blinding of participants and personnel (performance bias)</li> <li>(D) Blinding of outcome assessment (detection bias)</li> <li>(E) Incomplete outcome data (attrition bias)</li> <li>(F) Selective reporting (reporting bias)</li> </ul>		eration (sele	ction bia	s)					
<ul> <li>(C) Blinding of participants and personnel (performance bias)</li> <li>(D) Blinding of outcome assessment (detection bias)</li> <li>(E) Incomplete outcome data (attrition bias)</li> <li>(F) Selective reporting (reporting bias)</li> </ul>				0,					
<ul> <li>(D) Blinding of outcome assessment (detection bias)</li> <li>(E) Incomplete outcome data (attrition bias)</li> <li>(F) Selective reporting (reporting bias)</li> </ul>				rmance	bias)				
<ul> <li>(E) Incomplete outcome data (attrition bias)</li> <li>(F) Selective reporting (reporting bias)</li> </ul>					oraoj				
(F) Selective reporting (reporting bias)									
	(G) Other biases								

of miR-17 and miR-27 and increased the expressions of miR-146a and FoxP3 (P<0.05).

## 3.7 The Outcomes for JIA

Two RCTs reported on JIA. Ailioaie et al., 63 enrolled 32 patients, ages 8-16, and randomly assigned them to curcumin group (receiving 600 mg three times a day) or placebo group for 9 months, while all patients received standard treat. Their study showed that compared with the control group, ACR Pedi30, ACR Pedi50, ACR Pedi70, and ACR Pedi90 were significantly improved in the curcumin group (P<0.05), and the addition of curcumin (1800mg/day) did not increase the incidence of adverse events. In another study, 48 children (mean age, 13.8 years) with extensive oligoarticular and polyarticular JIA were randomly assigned to experiment group (receiving curcumin 1,200 mg+blue laser) or control group (receiving placebo) for 6 months. They found that curcumin+blue laser reduced disease activity according to the Disease Activity Score (JADAS-71) and pain levels (0-10 cm VAS), it also increased their functional activities of daily living (CHAQ scores) compared to placebo (64).

## 3.8 The Outcomes for Gout/Hyperuricemia


Only 65 reported on hyperuricemia. They found that curcumin intervention tended to reduce serum uric acid compared with placebo, but the difference was not statistically significant (P=0.532). There were no significant differences in urine uric acid clearance, fasting plasma glucose, and blood lipids between the two groups (P>0.05). Compared with the placebo group, curcumin did not increase the incidence of adverse events (P>0.05), and the most common adverse event was diarrhea.

# **4 DISCUSSION**

The mechanism of Curcumin and Curcuma longa Extract in the treatment of arthritis is shown in **Figure 14**.

# 4.1 Curcumin and *Curcuma longa* Extract for RA

This study systematically evaluated the clinical efficacy and safety of curcumin in the treatment of RA. The clinical efficacy



indicators DAS28, ESR, CRP and RF were lower than those in the control group, indicating that curcumin may improve the symptoms of RA and inhibit the inflammatory response. For safety, the addition of curcumin may not increase the probability of adverse events.

Sun et al. constructed a model of destabilization of the medial meniscus (DMM) in mice. They found that curcumin can reduce the expression of IL-1 $\beta$ , interferon- $\gamma$  (IFN- $\gamma$ ), IL17 $\alpha$ , IL-18, TNF- $\alpha$ , (vascular cell adhesion molecule 1 (VCAM1), and inhibit the inflammatory response in mice (69). This is similar to the findings of this study. This meta-analysis shows that curcumin can reduce inflammation indicators (RF, ESR, CRP). Recent studies have shown that curcumin may inhibit osteoclast (OC) differentiation in RA patients by down-regulating the expression of RANK gene and related proteins (70). Curcumin combined with methotrexate can effectively improve the joint and systemic symptoms of RA patients, and can improve bone destruction, and has a significant intervention effect on the RANK/RANKL/ OPG system (45). Curcumin can also inhibit the proliferation of fibroblast-like synovial cells (RA-FLS) and reduce the secretion of TNF- $\alpha$  and IL-6 in RA patients (71). Curcumin has a therapeutic effect on rats with type II collagen-induced arthritis (CIA). It can effectively inhibit macrophage-related inflammation and reduce the synovial homogenate of joints. It can also reduce the degradation of  $I\kappa B\alpha$  and the expression of COX-2 in RAW 264.7 cells (72). Xu et al. found that curcumin can reduce osteoclast production by inhibiting NF-KB signaling activation in RA (73). Curcumin can inhibit synovial angiogenesis in adjuvant arthritis (AA) rats. The mechanism may be related to reducing the expression of HIF-1a and downregulating the expression of target genes VEGF and VEGFR, which may be one of the mechanisms of its treatment of RA (74).

# 4.2 Curcumin and *Curcuma longa* Extract for OA

The meta-analysis of OA found that: (1) Compared with placebo, Curcumin and Curcuma longa Extract may reduce pain, improve joint function, and improve joint stiffness; and the addition of Curcumin and Curcuma longa Extract did not increase adverse events. (2) Curcumin and Curcuma longa Extract and NSAIDs have similar effects in improving joint pain, function, and stiffness, but with a lower incidence of adverse events. However, when curcumin was used in combination with NSAIDs, it improved joint pain, function, and stiffness more than NSAIDs alone, without increasing the rate of adverse events. But, due to the small number of RCTs, definitive conclusions are difficult to draw. (3) Compared with articular cartilage nutritional drugs, Curcumin and Curcuma longa Extract may improve joint pain, joint function, and joint stiffness without increasing the incidence of adverse events. (4) Compared with the control group, Curcumin and Curcuma longa Extract could reduce ESR and MDA levels. For SOD, GSH and COX-2, no clear conclusions could be drawn due to the small number of RCTs.

OA is a common chronic disease that mainly affects the knee joint, resulting in joint pain and loss of function (10). Knee OA carries a high societal cost, but management options are few and not ideal (75). Current medical treatment options are limited to analgesics, intra-articular corticosteroids, and NSAIDs (76). Although they have some efficacy in relieving pain, they are associated with gastrointestinal, renal, and cardiovascular complications and are generally contraindicated in patients with comorbidities (77). *Curcuma longa L.* has a long history of medicinal use (78–80). Curcumin, the main and most pharmacologically active ingredient in *Curcuma longa L.*, is "generally recognized as safe" by the US FDA (81–83). Current *in vitro* and preclinical studies have demonstrated the potential of curcumin, Curcuma longa Extract, and other Curcuma longa Extract multi-herbal preparations to delay OA progression and relieve OA-related pain (84–86).

Compared to previous systematic reviews (86, 87), this study pooled the largest number of RCTs, including more evidence and relevant content. This improves the quality and evidence of this study to provide more realistic and precise effect sizes. In addition, we found that OA patients in the curcumin group may be less likely to initiate pain medication and more likely to discontinue their existing pain medication because of its efficacy and better safety profile compared to the NSAIDs group. A previous systematic review report on the effects of Curcuma longa Extract on chronic inflammatory diseases, including rheumatic diseases, showed no significant between-group differences in inflammatory markers between Curcuma longa Extract and placebo (88), however, our results found that Curcuma longa Extract could improve ESR in OA patients. Although Curcumin and Curcuma longa Extract are effective and safe for OA, these results are only from short-term studies (maximum follow-up of 16 weeks), but are expected to be effective and safe drugs, as most current OA drug treatments have poor safety profiles (89). Furthermore, the meta-analyses showed significant heterogeneity, which could be explained by study-level covariates such as BMI and age.

# 4.3 Curcumin and *Curcuma longa* Extract for AS

AS mainly affects the axial skeleton, sacroiliac joints, and peripheral joints, causing structural changes and dysfunction, and is a chronic autoimmune inflammatory disease (90-92). Chronic inflammation of the spine resulting from the progression of AS leads to the formation of new bone on the spine, ultimately resulting in spinal immobility and stiffness (93). Previous studies have suggested that the pathogenesis of AS may be related to bacterial infection and human leukocyte antigen B27 (HLA-B27), and recent studies also suggest that T lymphocytes may mediate AS (94, 95). This notion is supported by changes in peripheral blood (PB) CD4+ T cell frequency in patients with AS, including an increase in Th17 frequency with Th2 and a decrease in CD4+CD25+ regulatory T (Treg) cells (93, 95-97). Numerous studies have shown that patients with AS have a decreased Treg/Th17 ratio, suggesting that immune phenotype changes may be one of the pathogenesis of AS, and that regulating the balance of Treg/Th17 may reduce disease activity (96, 98, 99). Treg/Th17 functional balance is critical for the prevention of autoimmune and inflammatory

diseases by preventing deleterious damage to the host and generating an effective immune response.

The current flow cytometry analysis of PB from AS patients showed that daily treatment with nanocurcumin for 4 months significantly increased the percentage of PB Treg cells compared to patients receiving placebo. Recent studies have found that curcumin can enhance Treg differentiation by increasing the expression of FoxP3 (94, 96). The results showed that FoxP3 gene expression was significantly increased in AS patients after nano-curcumin treatment, which confirmed the effect of nanocurcumin in enhancing Treg cells in these patients. In conclusion, this RCT study showed that administration of nanocurcumin (80 mg/kg bw/day) for 4 months increased the Treg population and the expression levels of FoxP3, TGF- $\beta$  and IL-10, as well as inhibited the IL-6 cytokine level. Furthermore, nanocurcumin could effectively alter the expression of Tregrelated miRNAs (decreased miR-17, miR-27 and increased miR-146a) during the follow-up of AS patients. More research is still needed in the future to further explore the exact biological process that curcumin modulates in AS patients. In addition, higher-quality multiple RCTs provide higher-quality evidence, thereby providing clinical value.

# 4.4 Curcumin and *Curcuma longa* Extract for JIA

The pathogenesis of JIA is related to a variety of factors, including genetic factors, immune responses, and environmental exposures. The pathogenesis of JIA is associated with aberrant activation of phagocytes (monocytes, macrophages, and neutrophils), suppression of Treg cells, hyperactivation of Th1 and Th17 cells, activation of NF-KB, and proinflammatory cytokines (IL-1, IL-6, IL-17, IL-18, IL-21, IL-22, IL-23, Interferon- $\gamma$  [IFN $\gamma$ ] and TNF- $\alpha$ ) (100–103). Currently, immunomodulatory drugs are the cornerstone of the treatment of JIA for these pathological processes of immune inflammation. Ailioaie et al., 63 included 32 children (ages 8-16 years) with JIA. They found that compared with the control group, ACR Pedi30, ACR Pedi50, ACR Pedi70, and ACR Pedi90 were significantly improved in the curcumin group (P<0.05), and the addition of curcumin (1800mg/day) did not increase the incidence of adverse events. In another study, 48 children (mean age, 13.8 years) with extensive oligoarticular and polyarticular JIA were randomly assigned to experiment group (receiving curcumin 1,200 mg+blue laser) or control group (receiving placebo) for 6 months. They found that curcumin+blue laser reduced disease activity according to the Disease Activity Score (JADAS-71) and pain levels (0-10 cm VAS), it also increased their functional activities of daily living (CHAQ scores) compared to placebo (64)

In the Miserocchi et al. (104) cohort study, 27 patients (age 17.4  $\pm$  8.9 years) with oligoarticular JIA-associated uveitis were recruited and received curcumin (500 mg per day) and JIA standard of care for 12 months. Uveitis is a serious extra-articular

complication of JIA. The severity of uveitis was assessed by slitlamp examination and FC500 laser flare at baseline and 1, 3, 6, 9, and 12 months after curcumin initiation. A total of 22 patients (81%) had inactive uveitis at the end of the study. Five patients remained stable, and three developed uveitis flares. During the study period, curcumin supplements were well tolerated and no one experienced ocular side effects or allergic reactions [7]. Although the above studies have shown curcumin in JIA with considerable evidence of its clinical adjunctive value, more largescale, randomized, placebo-controlled RCTs are needed in the future to confirm or revised the findings of these RCTs.

# 4.5 Curcumin and *Curcuma longa* Extract for Gout/Hyperuricemia

Hyperuricemia and gout is a metabolic abnormal syndrome caused by disturbance of purine metabolism. Because blood uric acid exceeds its saturation in blood or tissue fluid, sodium urate crystals are formed and deposited in the local joints, which induces local inflammation and tissue destruction symptoms (105, 106). The deposition of sodium urate crystals in the kidneys can cause acute kidney disease, chronic interstitial nephritis or kidney stones, which is called uric acid nephropathy. The common symptoms of hyperuricemia and gout are joint swelling and pain, starting from the feet, and then to the finger joints or wrists. Epidemiology shows that the number of patients with hyperuricemia and gout is increasing year by year worldwide, and it is expected to reach 1.42 billion in 2030 (107, 108). Patients with hyperuricemia and gout have poor compliance, with more than 50% of patients failing to follow doctor's orders for examination or re-examination, and the number of hyperuricemia and gout patients is still increasing (109; 110). Curcumin has shown potential effects in hyperuricemia and gout (65). Basic studies have shown that curcumin can inhibit the degradation of  $I\kappa B\alpha$ , the activation of NF-KB signaling pathway, and the inflammatory genes downstream of NF-KB in monosodium urate-stimulated THP-1-derived macrophages (111). Curcumin protected THP-1 and RAW264.7 cells from monosodium urate-induced mitochondrial damage by preventing the reduction of mitochondrial membrane potential, reducing mitochondrial reactive oxygen species, and then inhibiting the activity of the NLRP3 inflammasome. Animal studies have also shown that intraperitoneal injection of curcumin attenuates monosodium urate crystal-induced paw and ankle swelling, inflammatory cell infiltration, and MPO activity in a mouse model of acute gout. These results were related to inhibition of  $I\kappa B\alpha$  degradation, phosphorylation levels of NF- $\kappa$ B subunits (p65 and p50) (111). In vitro and in vivo studies on hyperuricemia have shown that curcumin and its degradation products have xanthine oxidase inhibition (112-114) and uric acid production by inhibiting URAT1 (115). Therefore, the drug may be effective in reducing serum uric acid. In addition, curcumin has been reported to reduce serum uric acid levels in other diseases (non-alcoholic fatty liver disease (NAFLD) and diabetes mellitus) (116; 117).

# 4.6 The Safety of Curcumin and Curcuma longa Extract

According to RCTs reporting adverse events, Curcumin and Curcuma longa Extract did not increase the occurrence of adverse events. According to the report of Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO) and European Food Safety Authority (EFSA), the acceptable daily intake (ADI) value of curcumin is 0-3 mg/kg; it is also approved by the US Food and Drug Administration as a botanical (79). According to the relevant safety and toxicity clinical trials, the acceptable dose of curcumin to obtain the maximum efficacy is 4-8 g/d. The dose of 8 g/d curcumin was shown to be safe in both phase I and II clinical trials (118), and it has been reported that curcumin up to 12 g/d is still tolerated by humans (119). Studies have shown that curcumin has no obvious sub-chronic toxicity damage after animal toxicity test, and has no potential mutagenic or teratogenic effects (120). For example, Krishnaraju et al. conducted toxicological evaluations on the safety of demethyl curcumin (DC) through acute oral administration, acute skin, primary skin and eye irritation, and dose-dependent 90-day subchronic toxicity studies. They found that the acute oral median lethal dose (LDso) of DC in female SD rats was >5 000 mg/kg, and the acute dermal LD50 was >2000 mg/kg, and no weight change or adverse effects were observed after autopsy, which proved the broad-spectrum safety of DC (121). Dandekar P et al. evaluated the toxicology of curcumin-loaded nanoparticles. The results of acute toxicity studies showed that the dose of 2000 mg/kg was non-toxic, and the subacute toxicity studies demonstrated the safety of long-term administration at the usual therapeutic dose of 100 mg/kg curcumin and twice the therapeutic dose (122).

# 4.7 The Strengths and Limitations

The strengths of this study is that to our knowledge, this is the first systematic review and meta-analysis of RCTs on the efficacy of turmeric and its curcumin on arthritis. The limitations of this study are: (1) Because curcumin has not been widely used in clinical practice, the sample size of the included studies is limited. (2) There may be omissions in the collection of documents and data extraction or the researcher's subjective judgment is not strict. (3) The RCTs included in this study were at high risk of bias. The authors of some RCTs were funded by drug manufacturers or were employees, which may introduce bias. (4) Languages are limited to English and Chinese, and related studies in other languages are not included.

# **5 CONCLUSION**

In summary, Curcumin and Curcuma longa Extract may improve symptoms and inflammation levels in people with arthritis. However, due to the low quality and small quantity of RCTs, the conclusions need to be interpreted carefully. Limited by the sample size of the included studies, large-sample, multicenter clinical trials are still needed for correction or verification.

# DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**. Further inquiries can be directed to the corresponding authors.

# **AUTHOR CONTRIBUTIONS**

TY and LZ contributed equally to this work. All authors contributed to the article and approved the submitted version.

## REFERENCES

- 1. Yoon E, Doherty JB. Arthritis Pain. J Gerontol Soc Work. (2008) 50 (Suppl 1) p:79–103. doi: 10.1080/01634370802137819
- Sudoł-Szopińska I, Schueller-Weidekamm C, Plagou A, Teh J. Ultrasound in Arthritis. Radiol Clin North Am (2017) 55(5):985–96. doi: 10.1016/ j.rcl.2017.04.005
- Bessis N, Decker P, Assier E, Semerano L, Boissier MC. Arthritis Models: Usefulness and Interpretation. Semin Immunopathol (2017) 39(4):469–86. doi: 10.1007/s00281-017-0622-4
- Glyn-Jones S, Palmer AJ, Agricola R, Price AJ, Vincent TL, Weinans H, et al. Osteoarthritis. *Lancet* (2015) 386(9991):376–87. doi: 10.1016/S0140-6736 (14)60802-3
- Mathew AJ, Ravindran V. Infections and Arthritis. Best Pract Res Clin Rheumatol (2015) 28(6):935–59. doi: 10.1016/j.berh.2015.04.009
- van der Woude D, van der Helm-van Mil AHM. Update on the Epidemiology, Risk Factors, and Disease Outcomes of Rheumatoid Arthritis. *Best Pract Res Clin Rheumatol* (2018) 32(2):174–87. doi: 10.1016/j.berh.2018.10.005
- O'Neill TW, McCabe PS, McBeth J. Update on the Epidemiology, Risk Factors and Disease Outcomes of Osteoarthritis. *Best Pract Res Clin Rheumatol* (2018) 32(2):312–26. doi: 10.1016/j.berh.2018.10.007
- Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken) (2020) 72(2):149–62. doi: 10.1002/acr.24131
- Abramoff B, Caldera FE. Osteoarthritis: Pathology, Diagnosis, and Treatment Options. *Med Clin North Am* (2020) 104(2):293-311. doi: 10.1016/j.mcna.2019.10.007
- Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet (2019) 393 (10182):1745–59. doi: 10.1016/S0140-6736(19)30417-9
- Martin A, Chopra R, Nicassio PM. Nonpharmacologic Pain Management in Inflammatory Arthritis. *Rheum Dis Clin North Am* (2021) 47(2):277–95. doi: 10.1016/j.rdc.2020.12.009
- VanSpil WE, Kubassova O, Boesen M, Bay-Jensen AC, Mobasheri A. Osteoarthritis Phenotypes and Novel Therapeutic Targets. *BiochemPharmacol* (2019) 165:41–8. doi: 10.1016/j.bcp.2019.02.037
- Gregori D, Giacovelli G, Minto C, Barbetta B, Gualtieri F, Azzolina D, et al. Association of Pharmacological Treatments With Long-Term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-Analysis. JAMA (2018) 320(24):2564–79. doi: 10.1001/jama.2018.19319
- Apostu D, Lucaciu O, Mester A, Oltean-Dan D, Baciut M, Baciut G, et al. Systemic Drugs With Impact on Osteoarthritis. *Drug Metab Rev* (2019) 51 (4):498–523. doi: 10.1080/03602532.2019.1687511
- England BR, Hershberger D. Management Issues in Rheumatoid Arthritis-Associated Interstitial Lung Disease. *CurrOpinRheumatol* (2020) 32(3):255– 63. doi: 10.1097/BOR.000000000000703
- Pope JE. Management of Fatigue in Rheumatoid Arthritis. RMD Open (2020) 6(1):e001084. doi: 10.1136/rmdopen-2019-001084
- Burmester GR, Pope JE. Novel Treatment Strategies in Rheumatoid Arthritis. Lancet (2017) 389(10086):2338–48. doi: 10.1016/S0140-6736(17) 31491-5

# ACKNOWLEDGMENTS

Figure 14 was created with BioRender.com.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.891822/ full#supplementary-material

- Marcu KB, Otero M, Olivotto E, Borzi RM. Goldring MB: NF-kappaB Signaling: Multiple Angles to Target OA. Curr Drug Targets (2010) 11:599– 613. doi: 10.2174/138945010791011938
- Suokas AK, Sagar DR, Mapp PI, Chapman V, Walsh DA. Design, Study Quality and Evidence of Analgesic Efficacy in Studies of Drugs in Models of OA Pain: A Systematic Review and a Meta-Analysis. Osteoarthritis Cartilage (2014) 22:1207–23. doi: 10.1016/j.joca.2014.06.015
- Sparks JA. Rheumatoid Arthritis. Ann Intern Med (2019) 170(1):ITC1– ITC16. doi: 10.7326/AITC201901010
- Schnitzer TJ. Update on Guidelines for the Treatment of Chronic Musculoskeletal Pain. Clin Rheumatol (2006) 25 Suppl 1:S22-9. doi: 10.1007/s10067-006-0203-8
- Wang W, Zhou H, Liu L. Side Effects of Methotrexate Therapy for Rheumatoid Arthritis: A Systematic Review. *Eur J Med Chem* (2018) 158:502–16. doi: 10.1016/j.ejmech.2018.09.027
- 23. Kotyla PJ, Engelmann M, Giemza-Stokłosa J, Wnuk B, Islam MA. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? *Int J Mol Sci* (2021) 22(5):2449. doi: 10.3390/ijms22052449
- Wang M, Liu L, Zhang CS, Liao Z, Jing X, Fishers M, et al. Mechanism of Traditional Chinese Medicine in Treating Knee Osteoarthritis. J Pain Res (2020) 13:1421–9. doi: 10.2147/JPR.S247827
- Hou PW, Fu PK, Hsu HC, Hsieh CL. Traditional Chinese Medicine in Patients With Osteoarthritis of the Knee. J Tradit Complement Med (2015) 5 (4):182–96. doi: 10.1016/j.jtcme.2015.06.002
- Ibáñez MD, Blázquez MA. Curcuma Longa L. Rhizome Essential Oil From Extraction to Its Agri-Food Applications. A Review. *Plants (Basel)* (2020) 10 (1):44. doi: 10.3390/plants10010044
- 27. Serpa Guerra AM, Gómez Hoyos C, Velásquez-Cock JA, Vélez Acosta L, Gañán Rojo P, VelásquezGiraldo AM, et al. The Nanotech Potential of Turmeric (Curcuma Longa L.) in Food Technology: A Review. Crit Rev Food Sci Nutr (2020) 60(11):1842–54. doi: 10.1080/10408398.2019.1604490
- Kotha RR, Luthria DL. Curcumin: Biological, Pharmaceutical, Nutraceutical, and Analytical Aspects. *Molecules* (2019) 24(16):2930. doi: 10.3390/ molecules24162930
- Menon VP, Sudheer AR. Antioxidant and Anti-Inflammatory Properties of Curcumin. Adv Exp Med Biol (2007) 595:105–25. doi: 10.1007/978-0-387-46401-5\_3
- Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, et al. Curcumin, the Golden Nutraceutical: Multitargeting for Multiple Chronic Diseases. Br J Pharmacol (2017) 174(11):1325–48. doi: 10.1111/ bph.13621
- Deeks J. J., Higgins J. P., Altman D. G. (2021a). Chapter 8: Assessing Risk of Bias in Included Studies, In: *Cochrane Handbook or Systematic Reviews of Interventions Version 6.2.0.* Editors Higgins J. P., Green S. (UK: The Cochrane Collaboration; ), 2021.
- 32. Karlapudi V, Prasad Mungara AVV, Sengupta K, Davis BA, Raychaudhuri SP. A Placebo-Controlled Double-Blind Study Demonstrates the Clinical Efficacy of a Novel Herbal Formulation for Relieving Joint Discomfort in Human Subjects With Osteoarthritis of Knee. J Med Food (2018) 21(5):511– 20. doi: 10.1089/jmf.2017.0065

- 33. Heidari-Beni M, Moravejolahkami AR, Gorgian P, Askari G, Tarrahi MJ, Bahreini-Esfahani N. Herbal Formulation "Turmeric Extract, Black Pepper, and Ginger" Versus Naproxen for Chronic Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Clinical Trial. *Phytother Res* (2020) 34(8):2067–73. doi: 10.1002/ptr.6671
- Badria F., El-Farahaty T., Shabana A., Hawas S., El-Batoty M. (2022). Boswellia–Curcumin Preparation for Treating Knee Osteoarthritis: A Clinical Evaluation. *Altern Complementary Ther*, 8(6):3410. doi: 1089/ 1076280027615746351-348.
- 35. Kizhakkedath R. Clinical Evaluation of a Formulation Containing Curcuma Longa and Boswellia Serrata Extracts in the Management of Knee Osteoarthritis. *Mol Med Rep* (2013) 8(5):1542–8. doi: 10.3892/ mmr.2013.1661
- Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, Grossi MG, et al. Efficacy and Safety of Meriva<sup>®</sup>, a Curcumin-Phosphatidylcholine Complex, During Extended Administration in Osteoarthritis Patients. *Altern Med Rev* (2010) 15(4):337–44.
- Belcaro G, Dugall M, Luzzi R, Ledda A, Pellegrini L, Cesarone MR, et al. Meriva®+Glucosamine Versus Condroitin+Glucosamine in Patients With Knee Osteoarthritis: An Observational Study. *Eur Rev Med Pharmacol Sci* (2014) 18(24):3959–63.
- Ross SM. Turmeric (Curcuma Longa): Effects of Curcuma Longa Extracts Compared With Ibuprofen for Reduction of Pain and Functional Improvement in Patients With Knee Osteoarthritis. *Holist NursPract* (2016) 30(3):183–6. doi: 10.1097/HNP.000000000000152
- Amalraj A, Varma K, Jacob J, Divya C, Kunnumakkara AB, Stohs SJ, et al. A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study. J Med Food (2017) 20(10):1022–30. doi: 10.1089/ jmf.2017.3930
- 40. Jacob J, Amalraj A, Raj KKJ, Divya C, Kunnumakkara AB, Gopi S. A Novel Bioavailable Hydrogenated Curcuminoids Formulation (CuroWhite<sup>™</sup>) Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients - A Randomized, Double Blind and Placebo Controlled Study. J Tradit Complement Med (2018) 9(4):346-52. doi: 10.1016/ j.jtcme.2018.06.001
- Henrotin Y, Malaise M, Wittoek R, de Vlam K, Brasseur JP, Luyten FP, et al. Bio-Optimized Curcuma Longa Extract is Efficient on Knee Osteoarthritis Pain: A Double-Blind Multicenter Randomized Placebo Controlled Three-Arm Study. *Arthritis Res Ther* (2019) 21(1):179. doi: 10.1186/s13075-019-1960-5
- Chandran B, Goel A. A Randomized, Pilot Study to Assess the Efficacy and Safety of Curcumin in Patients With Active Rheumatoid Arthritis. *Phytother Res* (2012) 26(11):1719–25. doi: 10.1002/ptr.4639
- Madhu K, Chanda K, Saji MJ. Safety and Efficacy of Curcuma Longa Extract in the Treatment of Painful Knee Osteoarthritis: A Randomized Placebo-Controlled Trial. *Inflammopharmacology* (2013) 21(2):129–36. doi: 10.1007/ s10787-012-0163-3
- 44. Javadi M, KhademHaghighian H, Goodarzy S, Abbasi M, Nassiri-Asl M. Effect of Curcumin Nanomicelle on the Clinical Symptoms of Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Controlled Trial. Int J Rheum Dis (2019) 22(10):1857–62. doi: 10.1111/1756-185X.13688
- Lin J, Yu H, Wang T. Curcumin Combined With Methotrexate in the Treatment of Rheumatoid Arthritis Bone Destruction. *Tianjin Tradit Chin Med* (2019) 36(03):238–41. doi: CNKI:SUN:TJZY.0.2019-03-008
- 46. Pourhabibi-Zarandi F, Rafraf M, Zayeni H, Asghari-Jafarabadi M, Ebrahimi AA. Effects of Curcumin Supplementation on Metabolic Parameters, Inflammatory Factors and Obesity Values in Women With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Phytother Res* (2022) 2022:17. doi: 10.1002/ptr.7422
- Hashemzadeh K, Davoudian N, Jaafari MR, Mirfeizi Z. The Effect of Nanocurcumin in Improvement of Knee Osteoarthritis: A Randomized Clinical Trial. *CurrRheumatol Rev* (2007) 16(2):158–64. doi: 10.2174/ 1874471013666191223152658
- Haroyan A, Mukuchyan V, Mkrtchyan N, Minasyan N, Gasparyan S, Sargsyan A, et al. Efficacy and Safety of Curcumin and Its Combination With Boswellic Acid in Osteoarthritis: A Comparative, Randomized,

Double-Blind, Placebo-Controlled Study. BMC Complement Altern Med (2018) 18(1):7. doi: 10.1186/s12906-017-2062-z

- Nakagawa Y, Mukai S, Yamada S, Matsuoka M, Tarumi E, Hashimoto T, et al. Short-Term Effects of Highly-Bioavailable Curcumin for Treating Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Prospective Study. J Orthop Sci (2014) 19(6):933–9. doi: 10.1007/s00776-014-0633-0
- Srivastava S, Saksena AK, Khattri S, Kumar S, Dagur RS. Curcuma Longa Extract Reduces Inflammatory and Oxidative Stress Biomarkers in Osteoarthritis of Knee: A Four-Month, Double-Blind, Randomized, Placebo-Controlled Trial. *Inflammopharmacology* (2016) 24(6):377–88. doi: 10.1007/s10787-016-0289-9
- 51. Khanna A, Das SS, Smina TP, Thomas JV, Kunnumakkara AB, Maliakel B, et al. Curcumagalactomannoside/Glucosamine Combination Improved Joint Health Among Osteoarthritic Subjects as Compared to Chondroitin Sulfate/Glucosamine: Double-Blinded, Randomized Controlled Study. J Altern Complement Med (2020) 26(10):945–55. doi: 10.1089/acm.2020.0128
- Shep D, Khanwelkar C, Gade P, Karad S. Safety and Efficacy of Curcumin Versus Diclofenac in Knee Osteoarthritis: A Randomized Open-Label Parallel-Arm Study. *Trials* (2019) 20(1):214. doi: 10.1186/s13063-019-3327-2
- 53. Thomas JV, Smina TP, Khanna A, Kunnumakkara AB, Maliakel B, Mohanan R, et al. Influence of a Low-Dose Supplementation of Curcumagalactomannoside Complex (CurQfen) in Knee Osteoarthritis: A Randomized, Open-Labeled, Active-Controlled Clinical Trial. *Phytother Res* (2021) 35(3):1443–55. doi: 10.1002/ptr.6907
- Pinsornsak P, Niempoog SThe Efficacy of Curcuma Longa L. Extract as an Adjuvant Therapy in Primary Knee Osteoarthritis: A Randomized Control Trial. J Med Assoc Thai (2012) 95 Suppl 1:S51–8.
- 55. Jamali N, Adib-Hajbaghery M, Soleimani A. The Effect of Curcumin Ointment on Knee Pain in Older Adults With Osteoarthritis: A Randomized Placebo Trial. *BMC Complement Med Ther* (2020) 20(1):305. doi: 10.1186/s12906-020-03105-0
- 56. Kuptniratsaikul V, Thanakhumtorn S, Chinswangwatanakul P, Wattanamongkonsil L, Thamlikitkul V. Efficacy and Safety of Curcuma Domestica Extracts in Patients With Knee Osteoarthritis. J Altern Complement Med (2009) 15(8):891–7. doi: 10.1089/acm.2008.0186
- 57. Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, Buntragulpoontawee M, Lukkanapichonchut P, Chootip C, et al. Efficacy and Safety of Curcuma Domestica Extracts Compared With Ibuprofen in Patients With Knee Osteoarthritis: A Multicenter Study. *Clin Interv Aging* (2014) 9:451–8. doi: 10.2147/CIA.S58535
- Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid Treatment for Knee Osteoarthritis: A Randomized Double-Blind Placebo-Controlled Trial. *Phytother Res* (2014) 28(11):1625–31. doi: 10.1002/ptr.5174
- Lopresti AL, Smith SJ, Jackson-Michel S, Fairchild T. An Investigation Into the Effects of a Curcumin Extract (Curcugen<sup>®</sup>) on Osteoarthritis Pain of the Knee: A Randomised, Double-Blind, Placebo-Controlled Study. *Nutrients* (2021) 14(1):41. doi: 10.3390/nu14010041
- 60. Kertia N, Asdie AH, Rochmah W, Marsetyawan. Ability of Curcuminoid Compared to Diclofenac Sodium in Reducing the Secretion of Cycloxygenase-2 Enzyme by Synovial Fluid's Monocytes of Patients With Osteoarthritis. *Acta Med Indones* (2012) 44(2):105–13.
- 61. Gupte PA, Giramkar SA, Harke SM, Kulkarni SK, Deshmukh AP, Hingorani LL, et al. Evaluation of the Efficacy and Safety of Capsule Longvida<sup>®</sup> Optimized Curcumin (Solid Lipid Curcumin Particles) in Knee Osteoarthritis: A Pilot Clinical Study. J Inflammation Res (2019) 12:145–52. doi: 10.2147/JIR.S205390
- Ahmadi M, Hajialilo M, Dolati S, Eghbal-Fard S, Heydarlou H, Ghaebi M, et al. The Effects of Nanocurcumin on Treg Cell Responses and Treatment of Ankylosing Spondylitis Patients: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Cell Biochem (2020) 121(1):103–10. doi: 10.1002/ jcb.28901
- Ailioaie C, Ailioaie LM. FRI0726- HPR Study on the Efficacy of Curcurmin Therapy in Early Stages of Juvenile Oligoarthritis. *Ann Rheumatic Dis* (2018) 7 7(Suppl 2):1810– 1811. doi: 10.1136/annrheumdis-2018-eular.6431%J

- Aloaic LM, Ailioaie C. FRI0728-HPR Cost: Reducing and Improving Quality of Life in Juvenile Arthritis by Blue Laser and Ultrabioavailablecurcumin. (2018) Annual European Congress of Rheumatology, 77(Suppl 2):1811–1811. doi: 10.1136/annrheumdis-2018-eular.6975%JAnnalsoftheRheumaticDiseases
- 65. Bupparenoo P, Pakchotanon R, Narongroeknawin P, Asavatanabodee P, Chaiamnuay S. Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial. J Diet Suppl (2021) 18(3):248–60. doi: 10.1080/19390211.2020.1757798
- 66. Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of Systemic Oxidative Stress by Curcuminoids in Osteoarthritis: Results of a Randomized Controlled Trial. J Diet (2016) Suppl. 13(2):209–20. doi: 10.3109/19390211.2015.1008611
- 67. Sterzi S, Giordani L, Morrone M, Lena E, Magrone G, Scarpini C, et al. The Efficacy and Safety of a Combination of Glucosamine Hydrochloride, Chondroitin Sulfate and Bio-Curcumin With Exercise in the Treatment of Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Study. *Eur J Phys Rehabil Med* (2016) 52(3):321–30.
- Wang Z, Jones G, Winzenberg T, Cai G, Laslett LL, Aitken D, et al. Effectiveness of Curcuma Longa Extract for the Treatment of Symptoms and Effusion-Synovitis of Knee Osteoarthritis : A Randomized Trial. Ann Intern Med (2020) 173(11):861–9. doi: 10.7326/M20-0990
- 69. Sun Y, Liu W, Zhang H, Li H, Liu J, Zhang F, Jiang T, Jiang S. Curcumin Prevents Osteoarthritis by Inhibiting the Activation of Inflammasome NLRP3. J Interf Cytok Res (2017) 37(10):439–55. doi: 10.1089/ jir.2017.0069. PMID: 29028430
- 70. Shang W, Zhao LJ, Dong XL, Zhao ZM, Li J, Zhang BB, et al. Curcumininhibits Osteoclastogenic Potential in PBMCs From Rheumatoid Arthritis Patients via the Suppression of MAPK/RANK/c-Fos/NFATc1 Signaling Pathways. Mol Med Rep (2016) 14(4):3620-6. doi: 10.3892/mmr.2016.5674
- Manca ML, Lattuada D, Valenti D, Marelli O, Corradini C, Fernàndez-Busquets X, et al. Potential Therapeutic Effect of Curcumin Loaded Hyalurosomes Against Inflammatory and Oxidative Processes Involved in the Pathogenesis of Rheumatoid Arthritis: The Use of Fibroblast-Like Synovial Cells Cultured in Synovial Fluid. *Eur J Pharm Biopharm* (2019) 136:84–92. doi: 10.1016/j.ejpb.2019.01.012
- Wang Q, Ye C, Sun S, Li R, Shi X, Wang S, et al. Curcumin Attenuates Collagen-Induced Rat Arthritis via Anti-Inflammatory and Apoptotic Effects. Int Immunopharmacol (2019) 72:292–300. doi: 10.1016/ j.intimp.2019.04.027
- An S, Han F, Hu Y, Liu Y, Li J, Wang L. Curcumin Inhibits Polyethylene-Induced Osteolysis via Repressing NF-κb Signaling Pathway Activation. Cell PhysiolBiochem (2018) 50(3):1100–12. doi: 10.1159/000494537
- 74. Cai J, Chang W, Shang W, Cai H. Effects of Curcumin on the Expression of HIF-1α, VEGF and VEGFR in Adjuvant Arthritis Model Rats. J Shandong Univ Tradit Chin Med (2015) 39(03):285–7. doi: CNKI:SUN:SDYX.0.2015-03-033
- Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M. The Global Burden of Hip and Knee Osteoarthritis: Estimates From the Global Burden of Disease 2010 Study. *Ann Rheum Dis* (2014) 73(7):1323–30. doi: 10.1136/ annrheumdis-2013-204763
- Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA. OARSI Guidelines for the non-Surgical Management of Knee, Hip, and Polyarticular Osteoarthritis. *OsteoarthrCartil* (2019) 27:1578–89. doi: 10.1016/j.joca.2019.06.011
- 77. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N. OARSI Recommendations for the Management of Hip and Knee Osteoarthritis, Part I: Critical Appraisal of Existing Treatment Guidelines and Systematic Review of Current Research Evidence. *OsteoarthrCartil* (2007) 15(9):981–1000. doi: 10.1016/j.joca.2007.06.014
- Ayati Z, Ramezani M, Amiri MS, Moghadam AT, Rahimi H, Abdollahzade A. Ethnobotany, Phytochemistry and Traditional Uses of Curcuma Spp. And Pharmacological Profile of Two Important Species (C. Longa and C. Zedoaria): A Review. *Curr Pharm Des* (2019) 25(8):871–935. doi: 10.2174/ 1381612825666190402163940
- Goel A, Jhurani S, Aggarwal BB. Multi-Targeted Therapy by Curcumin: How Spicy Is it? Mol Nutr Food Res (2008) 52(9):1010–30. doi: 10.1002/ mnfr.200700354

- Yue GG, Chan BC, Hon PM. Immunostimulatory Activities of Polysaccharide Extract Isolated From Curcuma Longa. Int J Biol Macromol (2010) 47(3):342-7. doi: 10.1016/j.ijbiomac.2010.05.019
- Sahebkar A. Are Curcuminoids Effective C-Reactive Protein-Lowering Agents in Clinical Practice? *Evid Meta-analysis Phytother Res* (2014) 28 (5):633–42. doi: 10.1002/ptr.5045
- Chandrasekaran CV, Kannan Sundarajan JRE, Gururaja GM. Immune-Stimulatory and Anti-Inflammatory Activities of Curcuma Longa Extract and its Polysaccharide Fraction. *Pharm Res* (2013) 5(2):71. doi: 10.4103/ 0974-8490.110527
- Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. Multitargeting by Turmeric, the Golden Spice: From Kitchen to Clinic. *Mol Nutr Food Res* (2013) 57(9):1510–28. doi: 10.1002/mnfr.201100741
- Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. Curcumin, a Component of Golden Spice: From Bedside to Bench and Back. *Biotechnol Adv* (2014) 32 (6):1053–64. doi: 10.1016/j.biotechadv.2014.04.004
- Peddada KV, Peddada KV, Shukla SK, Mishra A, Verma V. Role of Curcumin in Common Musculoskeletal Disorders: A Review of Current Laboratory, Translational, and Clinical Data. Orthop Surg (2015) 7(3):222– 31. doi: 10.1111/os.12183
- Bannuru RR, Osani MC, Al-Eid F. Efficacy of Curcumin and Boswellia for Knee Osteoarthritis: Systematic Review and Meta-Analysis. Semin Arthritis Rheumatol (2018) 48(3):416–29. doi: 10.1016/j.semarthrit.2018.03.001
- Wu J, Lv M, Zhou Y. Efficacy and Side Effect of Curcumin for the Treatment of Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. *Pak J Pharm Sci* (2019) 32(1):43–51.
- White CM, Pasupuleti V, Roman YM, Li Y, Hernandez AV. Oral Turmeric/ Curcumin Effects on Inflammatory Markers in Chronic Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Pharmacol Res* (2019) 146:104280. doi: 10.1016/ j.phrs.2019.104280
- Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. *Ann Rheum Dis* (2016) 75(3):552–9. doi: 10.1136/ annrheumdis-2014-206914
- Ji W, Li H, Gao F, Chen Y, Zhong L, Wang D. Effects of Tripterygium Glycosides on Interleukin-17 and CD4+CD25+CD127low Regulatory T-Cell Expression in the Peripheral Blood of Patients With Ankylosing Spondylitis. *BioMed Rep* (2014) 2:517–520. doi: 10.3892/br.2014.262
- Wright PB, McEntegart A, McCarey D, McInnes IB, Siebert S, Milling SW. Ankylosing Spondylitis Patients Display Altered Dendritic Cell and T Cell Populations That Implicate Pathogenic Roles for the IL-23 Cytokine Axis and Intestinal Inflammation. *Rheumatology* (2015) 55:120–132. doi: 10.1093/rheumatology/kev245
- Zhao S, Hu J, Wang J, Lou X, Zhou L. Inverse Correlation Between CD4 +CD25HighCD127low/– Regulatory T-Cells and Serum Immunoglobulin A in Patients With New-Onset Ankylosing Spondylitis. J Int Med Res (2011) 39:1968–1974. doi: 10.1177/147323001103900543
- Szalay B, Mészáros G, Cseh Á. Adaptive Immunity in Ankylosing Spondylitis: Phenotype and Functional Alterations of T-Cells Before and During Infliximab Therapy. *Clin Dev Immunol* (2012) 2012:1–8. doi: 10.1155/2012/808724
- Wang C, Liao Q, Hu Y, Zhong D. T Lymphocyte Subset Imbalances in Patients Contribute to Ankylosing Spondylitis. *Exp Ther Med* (2015) 9:250– 256. doi: 10.3892/etm.2014.2046
- Guo H, Zheng M, Zhang K. Functional Defects in CD4+ CD25high FoxP3+ Regulatory Cells in Ankylosing Spondylitis. Sci Rep (2016) 6:37559. doi: 10.1038/srep37559
- Wu Y, Ren M, Yang R. Reduced Immunomodulation Potential of Bone Marrow-Derived Mesenchymal Stem Cells Induced CCR4+ CCR6+ Th/Treg Cell Subset Imbalance in Ankylosing Spondylitis. *Arthritis Res Ther* (2011) 13:R29. doi: 10.1186/ar3257
- 97. Xueyi L, Lina C, Zhenbiao W, Qing H, Qiang L, Zhu P. Levels of Circulating Th17 Cells and Regulatory T Cells in Ankylosing Spondylitis Patients With an Inadequate Response to Anti-TNF-α Therapy. J Clin Immunol (2013) 33:151–161. doi: 10.1007/s10875-012-9774-0
- Zhong Y, Zhang B, Liao Z, Gu J. Assessment of Ankylosing Spondylitis by Serum Cytokine Profile. Int J Clin Exp Med (2016) 9:19302–19312.

- Handono K, Pratama MZ, Endharti AT, Kalim H. Treatment of Low Doses Curcumin Could Modulate Th17/Treg Balance Specifically on CD4+ T Cell Cultures of Systemic Lupus Erythematosus Patients. *Cent Eur J Immunol* (2015) 40:461–469. doi: 10.5114/ceji.2015.56970
- Lee JJY, Schneider R. Systemic Juvenile Idiopathic Arthritis. Pediatr Clin North Am (2018) 65(4):691–709. doi: 10.1016/j.pcl.2018.04.005
- Sen ES, Ramanan AV. Juvenile Idiopathic Arthritis-Associated Uveitis. Clin Immunol (2020) 211:108322. doi: 10.1016/j.clim.2019.108322
- Crayne CB, Beukelman T. Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis. *Pediatr Clin North Am* (2018) 65(4):657-74. doi: 10.1016/ j.pcl.2018.03.005
- Prakken B, Albani S, Martini A. Juvenile Idiopathic Arthritis. *Lancet* (2011) 377(9783):2138–49. doi: 10.1016/S0140-6736(11)60244-4
- 104. Miserocchi E, Giuffrè C, Cicinelli MV, Marchese A, Gattinara M, Modorati G, et al. Oral Phospholipidic Curcumin in Juvenile Idiopathic Arthritis-Associated Uveitis. Eur J Ophthalmol (2020) 30(6):1390–6. doi: 10.1177/ 1120672119892804
- 105. Sivera F, Andrés M, Quilis N. Gout: Diagnosis and Treatment. Med Clin (Barc) (2017) 148(6):271–6. doi: 10.1016/j.medcli.2016.10.019
- 106. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet (2021) 397 (10287):1843–55. doi: 10.1016/S0140-6736(21)00569-9
- Dehlin M, Jacobsson L, Roddy E. Global Epidemiology of Gout: Prevalence, Incidence, Treatment Patterns and Risk Factors. *Nat Rev Rheumatol* (2020) 16(7):380–90. doi: 10.1038/s41584-020-0441-1
- 108. Singh JA, Gaffo A. Gout Epidemiology and Comorbidities. Semin Arthritis Rheumatol (2020) 50(3S):S11–6. doi: 10.1016/j.semarthrit.2020.04.008
- 109. Yin H, Liu N, Chen J. The Role of the Intestine in the Development of Hyperuricemia. Front Immunol (2022) 13:845684. doi: 10.3389/ fimmu.2022.845684
- 110. Yang Y, Zhang JL, Zhou Q. Targets and Mechanisms of Dietary Anthocyanins to Combat Hyperglycemia and Hyperuricemia: A Comprehensive Review. Crit Rev Food Sci Nutr (2022) 62(4):1119–43. doi: 10.1080/10408398.2020.1835819
- 111. Chen B, Li H, Ou G, Ren L, Yang X, Zeng M. Curcumin Attenuates MSU Crystal-Induced Inflammation by Inhibiting the Degradation of Iκbα and Blocking Mitochondrial Damage. *Arthritis Res Ther* (2019) 21(1):193. doi: 10.1186/s13075-019-1974-z
- 112. Lin JK, Shih CA. Inhibitory Effect of Curcumin on Xanthine Dehydrogenase/ Oxidase Induced by Phorbol-12-Myristate-13-Acetate in NIH3T3 Cells. *Carcinogenesis* (1994) 15(8):1717–21. doi: 10.1093/carcin/15.8.1717
- Pauff JM, Hille R. Inhibition Studies of Bovine Xanthine Oxidase by Luteolin, Silibinin, Quercetin, and Curcumin. J Nat Prod (2009) 72(4):725–31. doi: 10.1021/np8007123
- 114. Shen L, Ji HF. Insights Into the Inhibition of Xanthine Oxidase by Curcumin. Bioorg Med Chem Lett (2009) 19(21):5990-3. doi: 10.1016/ j.bmcl.2009.09.076

- 115. Ao G-Z, Zhou M-Z, Li Y-Y, Li S-N, Wang H-N, Wan Q-W, et al. Discovery of Novel Curcumin Derivatives Targeting Xanthine Oxidase and Urate Transporter 1 as Anti-Hyperuricemic Agents. *Bioorg Med Chem* (2017) 25 (1):166–74. doi: 10.1016/j.bmc.2016.10.022
- 116. Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. Reduction of Atherogenic Risk in Patients With Type 2 Diabetes by Curcuminoid Extract: A Randomized Controlled Trial. J Nutr Biochem (2014) 25(2):144–50. doi: 10.1016/j.jnutbio.2013.09.013
- 117. Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. J Cardiovasc Pharmacol (2016) 68(3):223–9. doi: 10.1097/FJC.000000000000406
- Gao W, Chan JY, Wei WI, Wong TS. Anti-Cancer Effects of Curcumin on Head and Neck Cancers. *Anticancer Agents Med Chem* (2012) 12(9):1110–6. doi: 10.2174/187152012803529736
- Barati N, Momtazi-Borojeni AA, Majeed M, Sahebkar A. Potential Therapeutic Effects of Curcumin in Gastric Cancer. J Cell Physiol (2019) 234(3):2317–28. doi: 10.1002/jcp.27229
- Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The Essential Medicinal Chemistry of Curcumin. J Med Chem (2017) 60(5):1620– 37. doi: 10.1021/acs.jmedchem.6b00975
- 121. Krishnaraju AV, Sundararaju D, Sengupta K. Safety and Toxicological Evaluation of Demethylatedcurcuminoids; a Novel Standardized Curcumin Product. *Toxicology Mechanisms and Methods*, (2009) 19(6/7):447–60. doi: 10.1080/15376510903200766
- 122. Dandekar P, Dhumal R, Jain R. Toxicological Evaluation of pH-Sensitive Nanoparticles of Curcumin:Acute, Sub-Acute and Genotoxicity Studies. *Food Chem Toxicol* (2010) 48(8/9):2073–89. doi: 10.1016/j.fct.2010.05.008

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zeng, Yang, Yang, Yu, Li, Xiang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.